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1 Introduction 
1.1 Host-parasite relationships between man and protozoa  
Every infection is a battle between the parasite and the host (Playfair 1995).  
Occasionally, a parasite becomes extremely dangerous to humans (e.g., plague and 
influenza).  The Antonine Plague, from 165–180 AD, also known as the Plague of 
Galen, was an ancient pandemic of either smallpox or measles.  It caused up to 2,000 
deaths per day in Rome.  Total deaths were estimated at five million individuals.  The 
Spanish pandemic of influenza between 1918 and 1920 killed at least 25 million 
people worldwide.  The various stages and outcomes of infection as well as the main 
strategies of parasitic attack and host counter-attack are shown in the graph below.  
 
 
 
 
Fig. 1.  Various stages and outcomes of infection.  Shown are the main strategies of the parasite 
(left) and host (right). Taken from: (Playfair 1995). 
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1.2 Immunity 
The body surface is the first line of defense against a large number of 
microorganisms.  When this defense mechanism is penetrated, the innate immune 
system becomes activated.  Innate immunity, which involves dendritic cells as well as 
monocytes/macrophages, refers to non-specific defense mechanisms that appear 
immediately or within hours of the appearance of an antigen and are based on the 
non-clonal recognition of microbial components.  Innate immunity is evolutionary 
conserved and essential for multicellular organisms; it can be traced back to the 
earliest forms of life.  Innate immunity, also called non-specific, non-adaptive, 
natural, or native immunity, is particularly important in immuno-compromised 
patients who lack activated, adaptive immune responses.  Non-specific immune 
defenses are primed prior to the occurrence of infection and consist of phagocytic 
cells, mast cells, complement, natural killer (NK) cells, and cytokines.  Responses 
generated by the innate immune system are rapid and are often capable of eliminating 
infectious agents.  If the innate immune system fails, an adaptive (also known as 
acquired or specific) immune response will ensue, distinguishing between different 
microbes and molecules.  The components of this immune response include T and B 
lymphocytes and their products. 
 
1.3 Aleppo Evil 
1.3.1 Leishmaniasis 
The World Health Organization considers leishmaniasis to be one of the major 
tropical diseases and public health problems of developing countries 
(WorldHealthOrganization).  Additionally, leishmaniasis may occur in patients who 
have traveled to endemic areas (Harms, Schonian et al. 2003) as well as in people 
who have not (Bogdan, Schonian et al. 2001). 
Leishmaniasis is caused by an obligate, intracellular infection of macrophages with 
species of the eukaryotic genus Leishmania.  This protozoan haemoflagelate belongs 
to the order Kinetoplastida and the family Trypanosomatidae.  Leishmania spp. infect 
their mammalian hosts, including humans, in which they elicit a spectrum of diseases 
from cutaneous to mucocutaneous and visceral forms in diverse locations of the world 
(Pearson and Sousa 1996). At present, leishmaniasis threatens 350 million people in 
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88 countries (Desjeux 2001).  The variability of the clinical features results from both 
the diversity of the Leishmania species as well as the immune responses of the host.  
Approximately 1 to 1.5 million people suffer from local, self-healing, cutaneous 
leishmaniasis, which is caused by Leishmania major (L. major) and L. tropica  in 
Europe and the Near and Far East and by L. viannia braziliensis, L. viannia 
guyanensis, and L. mexicana in the Americas.  Cutaneous leishmaniasis causes skin 
lesions known as Oriental sores, Jericho Buttons, Baghdad boils, Delhi boils, as well 
as other common names.  L. major and L. tropica are biochemically distinct, cause 
slightly different skin lesions, and do not overlap geographically.  In cutaneous 
leishmaniasis, the replicating amastigotes are limited to tissue surrounding the initial 
bite site. 
Approximately 500,000 people contract visceral leishmaniasis each year, known in 
India as Dum-Dum fever or Kala-azar.  Although not restricted to India, visceral 
leishmaniasis, caused by L. donavani, L. infantum, and L. chagasi affect primarily the 
spleen and liver, but also the bone marrow.  In southern Sudan between 1989 and 
1994, Kala-azar reached epidemic and epizootics proportions, leaving approximately 
100,000 people dead (Dedet 2002). Individuals with chronic viscerotropic infection 
suffer from fever, fatigue, weight loss, peripheral edema, splenomegaly, 
hepatomegaly, anemia, and bleeding disorders; such infection results in 
immunosuppression and secondary infections, which is the usual cause of death. 
Mucocutaneous leishmaniasis is caused by L. braziliensis.  Skin lesions may be open 
and oozing, potentially spreading amastigotes to other parts of the body or to other 
individuals.  Secondary infections may occur coincidentally with primary infections 
or may occur many years after the primary infection has healed.  In some parts of 
South America, the disease is known as espundia or uta and refers to secondary 
lesions that occur in the mucous membranes, particularly in the nasal and oral regions, 
resulting in grossly destructive anomalies caused by disfiguring sores and gaping 
holes.  The nasal septum and other nasal/oral tissues appear to be “eaten away.”  
Espundia may develop metastatically from sores originally found elsewhere on the 
body.  Commonly, this form of leishmaniasis leads to the host’s death due to a 
secondary bacterial infection, pharyngeal obstruction, and/or malnutrition.  Invasion 
of the larynx may result in a loss of speech.  
Rarely, leishmaniasis is spread from a pregnant woman to her baby.  Additionally, 
leishmaniasis can be spread by blood transfusions and contaminated needles.  Due to 
Introduction                                                                                                               1-4   
its pathology, leishmaniasis leaves its victims scarred and disfigured, causing severe 
stigmatization among affected individuals, particularly children and women who are 
often deemed unsuitable for marriage or for raising children.  
 
 
 
Fig. 2.  Cutaneous leishmaniasis.  Classification is often obscured by the existence of a spectrum 
of intermediate forms.  
From Science Daily (Aug. 16, 2007), Dr Ross Boyle, University of Hull, United Kingdom — 
Flesh-eating disease appears to be on the rise due to global warming.  Should global warming 
continue to ravage our planet at current rates, the numbers of people suffering Leishmaniasis, a 
flesh-eating and sometimes fatal disease will increase dramatically, experts warn.  Leishmaniasis 
is caused by a parasite transmitted via sand fly bites usually found only in tropical climates.  
Rising temperatures will increase the number of countries the sand fly colonises, moving further 
north and through Europe. 
 
The Leishmania vector is the female sand fly of the genera Phlebotomus in the Old 
World and Lutzomya in the New World.  Sand flies are small blood-sucking insects 
that are capable of passing through certain kinds of mesh screens in windows and 
doors that are used in the fight against malaria; a very fine-mesh netting is needed for 
an effective barrier against sand flies as they are only about one-third the size of a 
typical mosquito.   
 
1.3.2 Leishmania genome 
The size of the Leishmania genome is approximately 3.55 × 107 bp and is organized 
into 34–36 chromosomes.  The parasite is a diploid organism but is functionally 
asexual.  It exhibits genomic plasticity that implies that certain genes, most likely vital 
or highly expressed genes, are variable in both size and number.  Of particular 
importance is that Leishmania spp., in contrast to most protozoa, do not undergo 
Introduction                                                                                                               1-5   
chromosome condensation during mitosis (Stiles, Hicock et al. 1999).  Leishmania 
parasites multiply by binary fission though assumptions of sexual reproduction due to 
their diploid genome have been made (Bastien, Blaineau et al. 1992; Gibson and 
Stevens 1999).  Homologous chromosomes vary in size not only between species but 
within clones of a single species (Britto, Ravel et al. 1998).  Chromosomal alterability 
in Leishmania is probably not caused by interchromosomal rearrangements, but rather 
by amplification/deletion events in sub-telomeric regions, accounting for the 
variability in chromosomal size (Victoir, Dujardin et al. 1995; Stiles, Hicock et al. 
1999).  In 1992, Bastien et al. suggested a ‘mosaic structure’ for Leishmania genomes 
with different cells that contain differently sized chromosomal homologs due to 
frequent amplification/deletion events (Bastien, Blaineau et al. 1992).  The open 
reading frames are arranged in long, polycistronic arrays.  Monocistronic mRNAs are 
created by post-transcriptional processing events.  The Leishmania genome contains 
repetitive DNA sequences  with a 58–60% G/C content; its coding regions have a 
higher G/C content than the non-coding regions, with 5’-coding regions having a 
lower G/C content than the 3’-coding regions.  Alonso et al. suggested that the high 
G/C content might reflect a more primitive nature (Alonso, Guevara et al. 1992).  The 
genes of Leishmania lack introns, but occur as single genes, paired genes, or repeated 
genes in tandem arrays, which vary in their flanking sequences, even between closely 
related genes.  Cis-splicing mechanisms have not been detected in any of the 
Leishmania genomes.  The most common microsatellite DNA motifs, among di-, tri-, 
and tetra-nucleotide repeat motifs, are (CA)n repeats, present on the chromosomes of 
Leishmania spp. (Rossi, Wincker et al. 1994).  Repetitive motifs are common to 
molecules exposed on the membranes of Leishmania.  Parasitic protozoa contain 
many peptides with repeating amino-acid domains, a structure often not present in 
their higher eukaryotic homologues, provoking elevated antibody responses (Kemp, 
Coppel et al. 1987; McCutchan, de la Cruz et al. 1988; Stiles, Hicock et al. 1999).  
  
1.3.3 History 
Leishmania infections can be traced back to Burmese amber from the Albians of the 
Lower Cretaceous period (105–100 million years ago).  Sand flies probably 
introduced trypanosomatids to dinosaurs.  This idea is based on the discovery of a 
blood-filled sand fly fossil (Palaeomyia burmitis) in Burmese amber that contained 
reptilian blood cells infected with the trypanosomatid, Paleoleishmania proterus.  The 
Introduction                                                                                                               1-6   
sand fly contained stages of a Leishmania trypanosomatid in both its proboscis and 
abdominal midgut (Poinar and Poinar 2004).  Some of the discovered blood cells, 
which were ascribed to amphibians, contained developing parasites.  The extinction of 
dinosaurs via sand fly-transmitted visceral Leishmania parasites was suggested in 
1991 by Desowitz (Desowitz 1991).  Based on the discovered fossils, it is estimated 
that sand flies fed on vertebrate blood 130 million years ago and became vectors for 
trypanosomatids approximately 115–120 million years ago (early Cretaceous) when 
the co-evolution of sand flies, trypanosomatids, and reptiles is assumed to have 
begun.  Furthermore, it is assumed that the parasite-host-vector relationship evolved 
in species, such as dinosaurs, where it became lethal and survived in hosts that had 
immunity against the parasites.  Descendents of these hosts appear to have survived, 
and present-day reptilian leishmaniasis appears to have little effect on the hosts 
(Telford 1995).  At present, sand flies of the genus Sergentomyia feed and transmit 
the related Sauroleishmania to snakes and lizards (Telford 1995).  The effects of 
Sauroleishmania infections have not been well studied and, therefore, are not well 
understood.  However, studies in which chameleons were infected with 
Sauroleishmania showed that none of the animals survived infection (Brygoo 1963).  
Inside the sand fly fossil, blood cell vacuoles were detected that bore a striking 
resemblance to parasitophorous vacuoles containing Sauroleishmania amastigotes, 
transmitted by the Old World sand fly Sergentomyia of present-day lizards (Telford 
1995). 
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Fig. 3.  Two blood cell nuclei with putative parasitophorous vacuole-containing amastigotes 
(arrow) from the midgut of the fossil sand fly.  Bar = 4 µm.  High similarity to a 
parasitophorous vacuole containing amastigotes of Sauroleishmania in an extent lizard (insert).  
From: (Poinar and Poinar 2004). 
 
Representations of skin lesions and facial deformities, as seen in cutaneous 
leishmaniasis, have been found on pre-Incan pottery from Ecuador and Peru dating 
back to the first century AD.  This evidence shows that cutaneous and mucocutaneous 
forms of leishmaniasis prevailed in the New World as early as this period.              
One of the first and most important clinical descriptions of leishmaniasis was made in 
1756 by the Englishman Alexander Russell following the examination of a Turkish 
patient.  Russell resided at this time in Aleppo of the Ottoman Empire (now Syria).  
The city was as large as other major European cities during this period with a 
population of 233,000 people.  During his 13 years of residence in Aleppo, Russell 
collected material on mores, climatology, flora, fauna, and various endemic diseases 
(Gelpi 1987).  Ultimately, he published his gathered information (Alex. Russell 1756) 
in which he described a cutaneous disease: 
 “Cutaneous disease, thought by some to be peculiar to this place, has acquired the 
name of Il mal d’Aleppo, or Aleppo evil, among the Europeans. The natives call it 
Habt is Senne, or Botch of a Year, from the supposed time of its duration. In 
Turkish, Haleb Choban, or the Aleppo ulcer. This disease is not, however, peculiar to 
this place, being almost as common at Antab, and all the other villages on the banks 
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of the rivers Sejour and Coik, as at this place; which favours the opinion of its being 
occasioned by the water.”  
Furthermore, he described both a female species (assumed to be L. major) and a male 
species (assumed to be L. tropica) as the origins of the above-described cutaneous 
disease: 
 “What is called the female species begins like the former; but after a month or two 
it becomes somewhat painful, encreases often to double the extent of the male, 
discharges a good deal of the ichorous matter from under the scab, and by degrees 
comes to have the appearance of an indigested scorbutic ulcer, with a livid circle 
round it; but seems to be no deeper than the tunica cellulosa. In this condition it 
remains for several months, and is in general about a year from its first appearance 
before it is cured; but this is not a thing certain, many getting well some months 
sooner, while others remain several months longer. After it is cicatrized, it leaves an 
ugly scar, which remains thro’ life, and for many months has a livid colour. When 
they are not irritated, they seldom give much pain.”  
Independently, Sir William Boog Leishman (1865–1926) and Charles Donovan 
(1863–1951) discovered the cause of Kala-azar at the beginning of the 20th century.  
The parasite was named L. donovani in memory of these two researchers.  In 1921, 
brothers Edouard and Etienne Sergent succeeded in proving that the vector for 
transmission of Leishmania parasites to mammals is the sand fly of the genus 
Phlebotomus (Sergent, Sergent et al. 1921).  
 
1.3.4 Leishmaniasis: disease and parasitic life-cycle 
There are two morphological forms of Leishmania, the promastigote and the 
amastigote.  The promastigote form of the parasite is found in female sand fly vectors 
of the genera Lutzomyia and Phlebotomus. 
The infection process begins with the bite of an infected host by a sand fly, resulting 
in the ingestion of amastigotes by the fly.  Leishmania parasites undergo 
metacyclogenesis in the vector, a process in which the parasites are transformed from 
poorly infective flagellated procyclic promastigotes into highly infective metacyclics 
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that move up the proboscis and clog the esophagus of the fly.  Feeding sand flies then 
disgorge promastigotes (6–8 µm) on the skin of the mammalian host where they may 
enter the bite wound.  Within their vertebrate host, the promastigotes are quickly 
taken up by tissue phagocytes (monocytes/macrophages and neutrophils) that 
accumulate at the infection site due to the damage created by sand fly feeding 
(Wilson, Innes et al. 1987).  The only cells in which Leishmania amastigotes are able 
to proliferate in the mammalian host are macrophages.  Within these cells, 
promastigotes lose their flagella and transform into non-motile amastigotes.  Upon 
entry into the mammalian host, promastigotes are immediately faced with the host’s 
innate immune system, lysis by complement, and destruction by macrophages.  
Leishmania promastigotes not only avoid destruction by complement and phagocytes 
but also actually dominate macrophages that are functionally arrested within the 
innate immune system.  Therefore, after the bite of an infected sand fly and the 
inoculation of promastigotes into the dermis, the promastigotes adhere to the 
macrophages via both type-I and type-III complement receptors (Mosser and 
Rosenthal 1993), the major cell surface protein gp63, and the glycoconjugate LPG 
(lipophosphoglycan), followed by their internalization through phagocytosis 
(Brittingham and Mosser 1996). 
 
 
Fig. 4.  A macrophage (orange) stretches its pseudopodia to engulf/endocytose an invading 
flagellated L. major promastigote. 
Photograph taken from the Web page of the Christian de Duve Institute of Cellular Pathology; 
Research Unit of Tropical diseases TROP. http://www.icp.be/trop/about/subject2.htm 
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The newly formed phagosome, a vacuole around the promastigote, undergoes 
maturation via fusion with endocytic organelles (i.e., endosomes and lysosomes), 
leading to the formation of the mature phagolysosome (Antoine, Prina et al. 1998).  
The maturation of the phagolysosome is important, as it becomes the microbicidal site 
within macrophages because of its acidic pH, lysosomal hydrolyzing enzymes, nitric 
oxide (NO), and other reactive oxygen intermediates.  The results of Desjardin et al. 
suggest that inhibition of phagolysosomal biogenesis by Leishmania represents an 
intramacrophage survival strategy used by promastigotes to establish infection 
(Desjardins and Descoteaux 1997) as well as protection against an acidic environment 
due to their sensitivity to low pH.  Delaying the above-described process extends the 
time during which promastigotes are able to differentiate into acidic pH-resistant 
amastigotes, normally a 48-hour process, subsequent to phagocytosis.  The 
cytodifferentiation from the promastigote to the amastigote that occurs in the 
phagolysosomal compartment of the macrophage is a transformation process that is a 
prerequisite for parasite survival.  Astonishingly, amastigotes do not merely tolerate 
low pH in the phagolysosome but are established within these compartments because 
an acidic pH is required for proliferation and expression of amastigote-specific genes 
(Chang and Dwyer 1976; Charest, Zhang et al. 1996).  Once the amastigotes 
proliferate, macrophages ultimately lyse, release new amastigotes, and are 
endocytosed by uninfected macrophages.  Phagocytosis of amastigotes appears to 
occur primarily through Fc receptors (FcRs) and complement receptor-type CR3; 
however, other unidentified receptors may participate in this process (Guy and 
Belosevic 1993).  While resident in macrophages, the parasite avoids triggering 
antimicrobial responses; however, it may be eliminated over time with the 
development of an effective adaptive immune response. 
Rogers et al. showed recently in an experimental study using mice that Leishmania 
parasites could influence the feeding behavior of sand flies so that infected flies 
become more persistent in feeding on their host if interrupted.  Furthermore, the 
parasites in the sand fly produce a filamentous proteophosphoglycan (fPPG) gel that 
impedes the flies gut and mouthparts and, consequently, interferes with feeding, 
leading to additional feeding on more hosts.  Hence, this behavior leads to a selective 
advantage of the parasite by increasing transmission (Rogers and Bates 2007). 
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Fig. 5.  Leishmania life cycle.  Leishmaniasis is transmitted by the bite of female sand flies.  The 
sand flies inject the infective metacyclic promastigotes during blood meals into their hosts.  
Metacyclic promastigotes are phagocytosed by macrophages, transform into amastigotes, and 
multiply in macrophages.  Sand flies feed on Leishmania-infected mammalian species, and 
ingest macrophages infected with amastigotes.  In the sand fly's midgut, the parasites differentiate 
into promastigotes, which multiply, differentiate into metacyclic promastigotes, and migrate to the 
sand fly’s proboscis.  Here, the cycle begins again.  Depending on the parasitic strain, it is possible 
to distinguish between a spectrum of clinical diseases: visceral Leishmaniasis, Kala-Azar, L. 
donovani; cutaneous Leishmaniasis, Oriental Sore, L. major; mucocutaneous leishmaniasis, 
Espundia, L. braziliensis.  Drawing taken from the Web page of Thomas P. Buckelew, Ph.D., 
Professor Emeritus. Drawn by Meghan Petrucci. http://workforce.cup.edu/Buckelew/ 
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1.3.5 Leishmania RNA virus 
The Leishmania RNA virus (LRV) is an ancient virus that co-evolved with its 
protozoan host.  Virus-like particles (VLP) have been found in lower eukaryotes, such 
as Leishmania spp., Entamoeba histolytica, and Trypanosoma spp.  The family 
Totiviridea includes three genera of dsRNA viruses: Totivirus, Giardiavirus, and 
Leishmaniavirus.  Two types of Leishmaniaviruses, which infect only protozoa, exist 
(types LRV1 and LRV2).  Viruses with non-segmented dsRNA genomes of 
approximately 5,200 bp in length have been identified in both L. braziliensis and L. 
major.  The lack of an infectious phase for these viruses suggests that LRV arose prior 
to the divergence of Old and New World parasites.  Genetic recombination is 
considered unlikely because of the asexual reproduction of Leishmania parasites.  
Patterson et al. showed that Leishmaniavirus exists in human biopsy material of 
Leishmania-infected patients (Saiz, Llanos-Cuentas et al. 1998).  Whether the 
presence of Leishmaniavirus alters parasitic phenotype and affects disease 
pathogenesis has yet to be addressed (Gupta and Deep 2007).  The study of 
Leishmaniaviruses is still in its infancy and is neither well reported nor understood. 
 
1.3.6 Leishmania/HIV co-infection 
Infection by two different intracellular pathogens of the same target cell will affect 
immune responses and might influence the expression and multiplication of either one 
or both pathogens. 
Leishmaniasis is an opportunistic infection that is particularly troublesome for 
patients with human immunodeficiency virus (HIV)/acquired immune deficiency 
syndrome (AIDS) in that both diseases attack the immune system and thereby worsen 
a patient’s already compromised ability to resist other infections.  Leishmaniasis 
accelerates the onset of AIDS by encouraging further opportunistic infections (e.g., 
pneumonia and/or tuberculosis) and, thus, reduces life expectancies of HIV patients 
(Anema and Ritmeijer 2005).  Leishmaniasis can be transmitted directly from person 
to person through the sharing of needles, as is often the case among intravenous drug 
users, the main population at risk for co-infection.  Although people are often bitten 
by sand flies infected with Leishmania, most do not develop leishmaniasis.  However, 
immunosuppressed people (e.g., those under immunosuppression for organ 
transplants, cancer patients, those with auto-immune diseases, and HIV-infected 
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people) quickly develop severe leishmaniasis (World Health Organization, Fact sheet 
N° 116, revised May 2000). 
Leishmania and HIV infect and multiply in macrophages that can lead to a 
dysregulation of the immune system.  Both infections mutually affect each other.  
Leishmania can induce HIV activation in both macrophages and T cells; in contrast, 
HIV can enhance intracellular growth of Leishmania in macrophages.  HIV destroys 
CD4+ T helper cells and gains access to all other cell types that express CD4, such as 
monocytes/macrophages and dendritic cells.  Progression to AIDS among HIV-
infected patients has been linked to active replication of HIV, induced by stimuli such 
as those caused by parasitic activation of immune cells (Wolday, Berhe et al. 1999). 
 
1.3.7 The Trojan horse of Leishmania 
Leishmania parasites exhibit a pronounced preference for macrophages although they 
have the capacity to infect a variety of other phagocytic and non-phagocytic 
mammalian cells.  L. major promastigotes secrete a Leishmania chemotactic factor, 
(LCF) that recruits solely PMNs (polymorphonuclear neutrophil granulocytes).  
Production of the chemokine IL-8 by inflammatory granulocytes appears to serve as 
an amplifying loop and attracts more PMNs to the site of inflammation.  Infection of 
PMNs with L. major leads to longevity of PMNs and apoptosis is delayed by 
approximately 24 hours.  IL-8 can prolong the life span of PMNs although it is 
assumed that L. major uses a non-IL-8 strategy as its anti-apoptosis mechanism.  
Neutrophils exposed to a chemoattractant (IL-8) extend the first pseudopod in the 
correct direction and sequentially measure the concentration of attractant at two points 
in the gradient. As long as the gradient is maintained the chemotactic response 
persists.  Only when the gradient is compromised, either by removal of the 
chemoattractant or by uniform distribution across the cell, does the response subside. 
PMNs phagocytose L. major but the promastigotes cannot multiply within these cells.  
The secretion of the chemokine IP-10 by PMNs is inhibited by L. major, which leads 
to a blockade of both NK- and Th1-cell recruitment. Instead, L. major induces the 
gene expression and secretion of the chemokines MIP-1α and MIP-1β that attract 
monocytes/macrophages to the site of infection.  An early hallmark of apoptosis is the 
appearance of phosphatidylserine on the outer leaflet of the plasma membrane, a 
process called membrane flip.  In the case of PMNs, the cell membrane sends an “eat 
me” signal to macrophages.  The now-apoptotic PMNs do not represent a threat to 
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phagocytic macrophages and do not activate macrophage antimicrobial effector 
functions.  Therefore, the function of these phagocytes is silenced.  PMNs become 
completely engulfed by macrophage phagosomes without any direct physical 
interaction with macrophage surface receptors.  This anti-inflammatory milieu in the 
macrophage is beneficial for the survival of L. major.  The anti-inflammatory 
cytokine expression of TGF-β becomes up-regulated and TNF-α secretion was 
suggested as a possible mediator of delayed macrophage apoptosis (Moore and 
Matlashewski 1994; Muller, van Zandbergen et al. 2001; Aga, Katschinski et al. 
2002; van Zandbergen, Hermann et al. 2002; van Zandbergen, Klinger et al. 2004). 
 
1.3.8 Th1 versus Th2 
Like all parasites, Leishmania protozoa have evolved specialized strategies to evade 
immune destruction and to complete their life cycles (Bogdan and Rollinghoff 1998).  
Several host- and parasite-specific factors play roles in the persistence of Leishmania 
within infected cells and influence the clinical manifestations of disease, including 
non-healing cutaneous ulcers and visceral forms.  Among these factors, the host 
cytokine response plays a key role by affecting innate, antimicrobial responses and by 
promoting the differentiation of a protective T-cell response (Scharton-Kersten and 
Scott 1995).  Following the survival of the innate immune response, amastigotes must 
evade the host’s adaptive immune response in order to establish a chronic infection.  
The role of macrophages in this process is the presentation of antigen and release of 
cytokines to T lymphocytes.  Leishmania-infected cells are defective in the expression 
of MHC class-ІІ molecules on the cell surface (Reiner, Ng et al. 1987).  Therefore, 
macrophages have a reduced capacity to directly interact with T cells, thus impairing 
the initiation of the acquired immune response (Farrell 2002).  The outcome of this 
combat between amastigotes and the adaptive immune system does not solely depend 
on Leishmania but also on the immunological competence of the host to combat 
parasite growth .  However, early infection determines outcome and is regulated by 
cytokine production (Chatelain, Varkila et al. 1992; Sypek, Chung et al. 1993).  
Resistance to Leishmania is associated with a IL-12-driven Th1-cytokine profile (IL-
2, IFN-γ, and TNF-α), whereas non-healing leishmaniasis forms are associated with 
an IL-4-driven Th2 response (IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, and TGF-β) 
(Pirmez, Yamamura et al. 1993; Sacks and Noben-Trauth 2002).  The inability of L. 
major parasites to drive early IL-12 production in either resistant (C57BL/6) or 
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susceptible (BALB/c) mouse strains is the reason for the initial Th2 response to L. 
major infection. 
When activated, Th2 cytokines inhibit the IL-12-driven, interferon-γ-dominated Th1 
response that promotes healing and parasite clearance by the down-regulation of IL-
12 and IFN-γ, as well as NO production of macrophages that is critical for 
macrophage leishmanicidal activity (Heinzel, Sadick et al. 1989; Chatelain, Varkila et 
al. 1992; Vouldoukis, Becherel et al. 1997).  In contrast, IL-12 production leads to a 
Th1 response in conjunction with IFN-γ production.  The activation of macrophages 
is essential for their leishmanicidal activity (Reed and Scott 1993; Sypek, Chung et al. 
1993; Gallin, Farber et al. 1995) and refers to a stage during which macrophages 
acquire functional changes compared with their resting state, including the activation 
of hydrolytic lysosomal enzymes, the release of NO and reactive oxygen 
intermediates (Hughes 1988; Alexander, Satoskar et al. 1999; Mossalayi, Arock et al. 
1999).  The latter two compounds are toxic to amastigotes; therefore, macrophages 
should be able to destroy and resolve the cause of infection and the infection itself 
over time.  
Nevertheless, one should keep clearly in mind that the Th1/Th2 response to 
Leishmania infection is always an interplay between both Th1 and Th2 responses.  It 
is not yet understood why in certain patients or mouse models one but not the other T-
cell response is primarily activated. 
The recent elucidation of the L. major genome revealed two genes (LmjF33.1740 and 
LmjF33.1750) that exhibit significant sequence identity with the mammalian 
cytokine, macrophage migration inhibitory factor (MIF) (Ivens, Peacock et al. 2005).  
The finding of these two genes led to the hypotheses that L. major might mimic its 
mammalian ortholog in a manner that serves to evade the host immune response.  
 
1.4 The Cytokine MIF 
1.4.1 Introduction 
In 1932, Rich and Lewis reported that a factor inhibited immune cell migration in 
vitro; this factor turned out to be MIF, which belongs to one of the first-described 
cytokines.  MIF was discovered, in context with delayed-type hypersensitivity, as a 
lymphocyte mediator that inhibited the random migration of macrophages (George 
and Vaughan 1962; Bloom and Bennett 1966; David 1966).  In 1989, MIF was cloned 
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for the first time (Weiser, Temple et al. 1989).  MIF, which exists as a single copy in 
mammals, is also present in a variety of infectious protozoa, such as L. major and 
Toxoplasma gondii.  It is hypothesized that MIF plays a role in these organisms by 
interfering with the immune response of their mammalian hosts.  Also is MIF present 
in non-infectious organisms such as Caenorhabditis elegans and Arabidopsis 
thaliana.  However, its function in these organisms is not well understood.  
MIF mRNA and protein are constitutively expressed and found in immune cells as 
well as in non-immune cells, including T cells, monocytes/macrophages, and 
parenchymal cells within the heart, kidney, liver, brain, and lungs, as well as the 
differentiating cells of the eye lens (Wistow, Shaughnessy et al. 1993).  MIF is found 
in preformed cytoplasmic pools, and at serum concentrations of 2 to 6 ng/ml in 
healthy individuals (Calandra, Echtenacher et al. 2000), with peak levels in the 
morning (circadian rhythm) (Petrovsky, Socha et al. 2003) and is ready to be released 
during an immune response, unlike other cytokines that require transcriptional 
activation and mRNA translation prior to release.  MIF also has a central role in the 
autocrine/paracrine activation of macrophages. 
 
1.4.2 Structure and tautomerase/isomerase activity of MIF 
In 1996, MIF, a 12.5-kDa protein, was successfully crystallized by three separate 
research groups (Kato, Muto et al. 1996; Sun, Bernhagen et al. 1996; Suzuki, 
Sugimoto et al. 1996), forming a new protein class, the tautomerase/MIF-fold and 
superfamily (Rosengren, Bucala et al. 1996).  MIF, a trimer composed of identical 
subunits, consists of three β-sheets that form a barrel surrounded by six α-helices.  
Each monomer consists of a βαβββαββ motif.  
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Fig. 6  Three-dimensional ribbon diagram of human MIF, revealing its homotrimeric subunit 
structure.  Each color resembles one monomer.  
 
MIF has the same three-dimensional structure as the microbial enzymes, CHMI (5-
carboxymethyl-2-hydroxymuconate isomerase) and 4-OT (4-oxalcrotonate 
tautomerase), although there is no sequence homology among them .  MIF possesses 
catalytic activity, including tautomerase and oxido-reductase activity.  After the post-
translational removal of the initiating methionine, Pro-1 is the catalytic residue.  To 
date, no physiological substrate for this catalytic site has been determined.  The non-
physiological substrate, the D-isomer of dopachrome (2-carboxy-2,3-dihydroindole-
5,6-quinone) is converted to DHICA (5,6-dihydroxyindole-2-carboxylic acid) 
(Rosengren, Aman et al. 1997).  However, whether the pro-inflammatory role of MIF 
is based on its enzymatic activity is still under discussion.  MIF also effects the enol-
keto tautomerization of the substrates phenylpyruvate and hydroxyphenylpyruvate.  
ISO-1 [(S,R)-3-4(-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester], 
an inhibitor of MIF N-terminal tautomerase activity (Lubetsky, Dios et al. 2002; Al-
Abed, Dabideen et al. 2005), was shown to inhibit the catalytic activity and some of 
the biologic activities of MIF. 
 
1.4.3 The role of TPOR activity in MIF function 
In 1996, Kleemann et al. demonstrated that MIF was able to mediate catalytic 
oxidoreductase activity (Kleemann, Kapurniotu et al. 1998) through its Cys-X-X-Cys 
(CXXC, where X is any amino acid) motif.  This motif, between residues 57 and 60 
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of MIF, is a conserved region that is found in the thioredoxin (Trx) superfamily of 
thiol-protein oxidoreductases (TPORs).  MIF shares this motif with other enzymes, 
such as Trx, protein disulfide isomerase, and glutaredoxin.  In the case of MIF, the 
CXXC motif is a Cys-Ala-Leu-Cys (CALC).  The CALC motif is conserved in all 
mammalian MIF orthologs; similar motifs were found in parasitic proteins of Brugia 
malayi and Wucheria bancrofti.  MIF fulfils the requirements for the “extended TPOR 
motif” in having a Phe at position -7 and a Leu at position -10 of its CXXC motif. 
Under oxidizing conditions, MIF disulfide bridges between the Cys residues 57 and 
60 are formed (Kleemann, Kapurniotu et al. 1998).  
MIF exhibits CXXC-dependent TPOR activity with which it can undergo reversible 
oxidation/reduction reactions that catalyze disulfide/dithiol compounds (e.g., insulin 
and MHC class ІІ molecules).  
TPORs regulate protein folding and defend against oxidative and oxygen species 
(ROS) stress.  Trx has been reported to interact with ASK-1 (apoptosis signal-
regulating kinase-1), JAB1 (c-Jun activation domain binding protein-1), and Ref-1 
(regulator of fusion-1) to control cellular signaling processes (Saitoh, Nishitoh et al. 
1998; Hwang, Ryu et al. 2004).  Trx was found to inhibit the apoptosis of immune 
cells through its TPOR site (Baker, Payne et al. 1997; Powis, Mustacich et al. 2000; 
Andoh, Chock et al. 2002).  MIF was discovered to have certain characteristics of 
Trx, including intra- and extracellular activities, secretion without a leader sequence, 
and blockade of apoptosis, although it is not structurally homologous to the TPOR 
proteins.  MIF is secreted upon H2O2 stimulation from macrophages (Kleemann, 
Mischke et al. 1998; Takahashi, Nishihira et al. 2001; Fukuzawa, Nishihira et al. 
2002; Sakamoto, Fujie et al. 2002) and can therefore be considered an indicator of 
oxidative cell stress.  MIF(50–65) was found to reduce cellular ROS (e.g., H2O2,  O2-) 
within cells (Sun, Li et al. 2004; Matsuura, Sun et al. 2006), trigger mitogen-activated 
protein kinase (MAPK) activity (Nguyen, Beck et al. 2003), and bind to the MIF 
receptor CD74 (“MSc thesis”; Diplomarbeit).  Cys60 was shown to be important in 
MIF leishmanicidal activity (Kleemann, Kapurniotu et al. 1998) as well as in CD74 
interactions that were described using a C60S MIF mutant that exhibited reduced 
binding potency to CD74 (“MSc thesis”; Diplomarbeit).  Furthermore, double 
mutations within the MIF CXXC motif showed altered protein folding.   
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1.4.4 MIF polymorphisms and expression 
The genomic organization of the human MIF gene was described initially by Paralkar 
and Wistow in 1994 (Paralkar and Wistow 1994) who were the first to clone this 
gene.  The human MIF gene is localized on chromosome 22, region 11 (22q11.2).  
The gene comprises 3 exons of 205, 173, and 183 bp separated by 2 introns of 189 
and 95 bp (GeneBank Accession number: L19686;  
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=307284).  The MIF 
gene has a rather small 1.7 Kb size and is expressed as a single mRNA transcript in 
the human.  Its open reading frame is 345 bp, and encodes a 115-amino acid 
polypeptide with a calculated molecular mass of 12,650 Da.  MIF is distinct from that 
of conventional or secretory proteins by its lack of a hydrophobic leader sequence.  
This finding led to the assumption of a non-classical secretion pathway for MIF.  
Subsequent studies revealed a 5’-flanking sequence of 1 kb and a 3’-flanking 
sequence of 250 bp.  Transcription of MIF was found to begin at -97, a region that is 
flanked by a cAMP-response element (CRE) and multiple SP1 sites.  No classic 
eukaryotic TATA box (also called Goldberg-Hogness box) was found (Lifton, 
Goldberg et al. 1978), leading to the identification of a TATA-less promoter (Paralkar 
and Wistow 1994).  Northern blot analysis of mRNA collected from multiple tissues 
and organs identified a single transcript of approximately 800 nucleotides in the 
human and the mouse. 
Gene polymorphisms have been shown to have an impact on the pathogenesis of both 
autoimmune and inflammatory diseases.  The MIF gene was revealed to have a 
polymorphism at position -794 of the promoter region, a tetranucleotide CATT-repeat 
(Paralkar and Wistow 1994; Baugh, Chitnis et al. 2002).  Homozygous and 
heterozygous individuals for 5-, 6-, 7-, or 8-CATT repeats were subsequently 
identified.  MIF promoter activity is proportional to the number of CATT repeats; 5-
CATT repeats lead to low MIF expression levels and greater-than-5 CATT repeats 
lead to high MIF expression levels (Baugh, Chitnis et al. 2002).  The latter, in 
conjunction with various substitutions at position -173, showed higher occurrences in 
individuals with inflammatory diseases.  At position -173 of the human MIF 
promoter, a single nucleotide polymorphism (SNP) of G to C was discovered (Donn, 
Shelley et al. 2001).  Other SNPs of T to C at position +254 in intron 1 and C to G- at 
+656 in intron 2 have been reported (Donn, Alourfi et al. 2002).  At present, it is not 
known whether the intronic SNPs regulate MIF expression.  Transcriptional activity 
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of the promoter is affected by the -794 CATT repeat and possibly by the -173 SNP in 
the gene’s promoter.  It is assumed that the transcription factor Pit-1 (pituitary-
specific transcription factor 1), also known as POU1F1, might influence an 
individual’s genetic susceptibility by enhancing MIF expression and augmenting 
inflammatory responses.  Having a C nucleoside at position -173 leads to an AP-4 
(activator protein)-binding site although its precise function is not yet known. 
 
1.4.5 MIF as a ligand 
The requirement for a cell surface receptor was debated until 1999 when Mitchell et 
al. (Mitchell, Metz et al. 1999) determined that MIF was able to stimulate 
intracellular pathways.  Leng et al. showed that MIF mediates signal transduction 
through the cell surface form of the MHC class ΙΙ-associated chaperone, invariant 
chain (Ii) or CD74 (Leng, Metz et al. 2003).  CD74, a homotrimer, is a 32–41 kDa, 
type-ΙΙ transmembrane protein with a cytosolic domain of 29–46 amino acids.  The 
differences in size emerge from two, in-phase, alternative initiation codons 
(Arunachalam, Lamb et al. 1994) and N-glycosylation.  MIF binding to sCD7473-232 
showed an equilibrium Kd (dissociation constant) of 9 × 10-9 to 2.3 × 10-10.  The 
measured Kd might differ from the in vivo Kd because of the CD74 transmembrane 
domain that requires removal prior to cloning and expression.  This removal might 
result in altered  oligomerization of native CD74.  CD74 has been known to process 
and transport MHC class-ΙΙ molecules from the endoplasmic reticulum to 
compartments of MHC class-ΙΙ loading (Cresswell 1994; Ashman and Miller 1999).  
CD74 is  expressed in MHC class-II-expressing cells, but, upon stimulation can also 
be found in MHC class-II-negative cells; this finding advanced the hypothesis that a 
protein like CD74  may have multiple, possibly unrelated, functions.  Recent work 
suggested that CD44 is the signal-transducing molecule of the MIF-CD74 receptor 
complex (Meyer-Siegler, Leifheit et al. 2004; Shi, Leng et al. 2006).  
The mechanism of MIF signaling in inflammatory atherogenic processes was 
discovered very recently.  The MIF monomer shows three-dimensional homology to 
the CXCL8 dimer (Sun, Bernhagen et al. 1996).  Consistently, MIF, which features a 
pseudo-ELR motif (N-terminal Glu-Leu-Arg), has the ability to bind to CXCR2, 
which is the CXCL8  receptor .  Not only is MIF able to induce neutrophil chemotaxis 
through CXCR2 (Bernhagen, Krohn et al. 2007), but it also promotes the recruitment 
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of both monocytes and T cells via interactions with CXCR2 and CXCR4.  
Interestingly, MIF/CXCR2 binding also involved CD74 indicating that MIF signals 
via a functional CXCR/CD74 super-complex, demonstrating its importance in 
inflammatory processes and atherogenic cell recruitment.  In conclusion, MIF is not 
only a ligand for CD74, but also directly activates the chemokine receptors, CXCR2 
and CXCR4.  
 
1.4.6 MIF function  
During infection, the host responds with the activation of the hypothalamic-pituitary-
adrenal (HPA) axis and, hence, the release of glucocorticoid hormones (anti-
inflammatory mediators) produced in the adrenal cortex.  Hormones are (bio-) 
chemical messengers that carry signals from one group of cells to another via the 
blood stream in an endocrine fashion to regulate the function of their target cells.  
Surprisingly, MIF production is induced after release of, as well as after treatment 
with, glucocorticoids.  Once released, MIF antagonizes the actions of glucocorticoids 
by the following mechanisms: (i) MIF counteracts the inhibition of NF- B by 
preventing the glucocorticoid-induced increase in cytosolic I B , the inhibitor of NF-
кB, and/or (ii) MIF inhibits the expression of MKP-1 (MAPK phosphatase-1), the 
inhibitor of extracellular signal-regulated kinase (ERK1/2), p38 and JNK MAPK.  
After treatment with either cortisol or dexamethasone at concentrations of 10-6 M, the 
dose-response curve of macrophage MIF production is bell-shaped.  This dose-
response curve is also seen in MIF-producing macrophages after stimulation with pro-
inflammatory stimuli, such as TNF-α, IFN-γ, endotoxin, and exotoxin.  The bell-
shaped curve might protect the host from the deleterious effects of exuberant 
concentrations of MIF.  Mechanistically, our knowledge of MIF secretion is still 
limited, although recently it was shown that MIF is secreted via a non-classical 
pathway possibly involving an ABCA1 transporter (Flieger, Engling et al. 2003).  
Notably, MIF was identified as a negative regulator of the tumor suppressor p53 
(Hudson, Shoaibi et al. 1999).  p53 inhibition requires the upstream activation of 
ERK1/2, phospholipase A2 (cPLA2), arachidonic acid, and COX2.  Furthermore, 
MIF not only activates the ERK1/2 pathway but also JNK (c-jun N-terminal kinase), 
p38 MAPK [also known as DC-2-related protein kinase or CSBP (cytokine 
suppressive anti-inflammatory drug binding protein)] (Roger, Chanson et al. 2005; 
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Aeberli, Yang et al. 2006). MIF also activates NF-κB in B cells (Starlets, Gore et al. 
2006). 
Lipopolysaccharide (LPS), the major component of the outer membrane of Gram-
negative bacteria, binds to Toll-like receptor 4 (TLR4).  The expression of TLR4 is 
up-regulated by MIF through the ETS transcription factor, PU.1 .  After binding of 
LPS to the LPS-binding complex, composed of TLR4, CD14, and LBP 
(lipopolysaccharide-binding protein), NF-κB signaling followed by TNF-α expression 
is stimulated.  This activation leads to the TNF-α-induced release of MIF from 
macrophages.  Preformed MIF is released within six hours after stimulation with LPS 
(Bacher, Meinhardt et al. 1997).  As a consequence, MIF expression is up-regulated 
and the cytoplasmic MIF pool is replenished within 24 hours of LPS stimulation.  
MIF promotes inflammatory responses by inducing TNF-α, IFNγ, IL-1β, IL-2, IL-6, 
IL-8, IL-12, CXCL2, NO, MMP (matrix metalloproteinase), cPLA2, and, 
consequently, arachidonic acid and its products, leukotrienes and prostaglandins.  
 
1.4.7 MIF and ERK1/2 
The activation of ERK has been shown to be required for inflammation, immune 
regulation, and cell proliferation.  
MIF stimulation is associated with the protein kinase A (PKA)-dependent serine 
phosphorylation of both CD74 and CD44 (Shi, Leng et al. 2006).  Upon either 
treatment with MIF or after the endogenous release of MIF, the p44/p42 ERK 
subfamily of the MAPKs is phosphorylated (Mitchell, Metz et al. 1999).  Not only 
does ERK activation through MIF persist for up to 24 hours (Mitchell, Metz et al. 
1999) but also is exogenous MIF able to stimulate the activation of the classical Raf-
1/MEK/ERK MAPK pathway within a few minutes (Lue, Kapurniotu et al. 2006).  
Activation of the ERK pathway results in the phosphorylation and activation of 
certain cytosolic proteins, such as P90rsk, c-myc, and cPLA2 (Hayakawa, Ishida et al. 
1993; Denhardt 1996).  cPLA2 mediates the production of the pro-inflammatory 
molecule arachidonic acid, the precursor of prostaglandins and leukotrienes, which 
play roles in inflammatory processes; the phosphorylation and activation of cPLA2 by 
MIF requires ERK activation (Mitchell, Metz et al. 1999).  
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1.4.8 MIF and the tumor suppressor p53 
Tumor suppressor genes slow cell division, contribute to DNA repair, and induce 
apoptosis.  When tumor suppressor genes fail to function properly due to mutations or 
pathogenic regulation, cells can grow out of control, leading to cancer.  In the case of 
neoplasia, tumor suppressor genes become disabled, allowing cells to bypass 
senescence and, instead of succumbing to apoptosis, continue dividing for additional 
generations.  Therefore, the tumor suppressor protein p53 is often referred to as a 
“gatekeeper” for cell growth and division and “guardian of the genome” (Levine 
1997; Ryan, Phillips et al. 2001; Fingerle-Rowson, Petrenko et al. 2003).  The p53 
protein, encoded by the TP53 gene, is mutated in over 50% of all human cancers.  The 
p53 protein is a transcription factor that can mediate many of its downstream effects 
by enhancing the rate of transcription through either the activation or repression of 6–
7 known genes.  The human p53 protein, which plays a role in triggering apoptosis, 
contains 393 amino acids and is divided into four domains (Levine 1997; Ryan, 
Phillips et al. 2001).  The sequence-specific, DNA-binding domain of p53 is localized 
between amino acid residues 102 and 292.  p53 has a short half-life (~ 20 min) and is 
therefore present at low concentrations in cells.  In response to DNA damage, the p53 
half-life increases and the rate of translational initiation of p53 mRNA in cells 
becomes enhanced.  This increase in p53 levels is proportional to the extent of DNA 
damage.  p53 transcriptional activation is negatively regulated by the adenovirus E1B-
55Kd protein, the human MDM2 protein, and MIF (Levine 1997; Hudson, Shoaibi et 
al. 1999; Ryan, Phillips et al. 2001).  MIF inhibits p53-mediated growth arrest, gene 
activation, and apoptosis.  Furthermore, MIF is able to inhibit the transcription of p21, 
cyclin G, and the pro-apoptotic protein, Bax through p53 (Hudson, Shoaibi et al. 
1999).  During inflammatory diseases, a combination of interactions between MIF, 
NO, and p53 can be observed.  At the site of inflammation, macrophages release NO 
to mediate macrophage apoptosis as part of their antimicrobial repertoire (Messmer 
and Brune 1996; MacMicking, Xie et al. 1997).  Hudson et al. could demonstrate that 
MIF treatment suppressed NO-induced apoptosis in a dose-dependent manner 
(Hudson, Shoaibi et al. 1999). 
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Fig. 7.  RAW264 macrophages were first treated for 24 hours with 25, 50, 100, or 200 ng/ml MIF, 
and then with 250 µM or 1 mM SNP (NO-releaser).  After 2 days, cells containing condensed or 
fragmented DNA were scored as apoptotic after fixation with paraformaldehyde and staining with 
Hoechst 33258.  MIF treatment was capable of suppressing NO-induced apoptosis in a dose-
dependent manner.  Taken from: (Hudson, Shoaibi et al. 1999). 
 
MIF interference with the transcriptional activity of p53, leading to p53 inhibition and 
prevention of apoptosis, may represent a cancer risk factor during certain chronic 
inflammatory diseases (Hudson, Shoaibi et al. 1999; Mitchell and Bucala 2000).  
Such diseases include colon cancer in ulcerative colitis or Crohn’s disease (Ekbom, 
Helmick et al. 1990; Ekbom 1998), gastric cancer in Heliobacter pylori infection 
(Graham 2000), and urinary bladder cancer in the parasitic disease, Schistosomiasis 
(Mostafa, Sheweita et al. 1999). 
 
1.4.9 Role of MIF in infectious diseases 
The main virulence factor of Gram-negative bacteria (such as E. coli), is endotoxin, or 
LPS.  After LPS challenge in infected mice, an increase in MIF serum levels with a 
peak at 20 hours was detected.  Protection from lethal endotoxemia in mice was 
discovered after treatment with anti-MIF (Bernhagen, Calandra et al. 1993). Calandra 
et al. hypothesized that anti-MIF therapy might be useful to protect the host from 
harmful cytokine overburden, and in vivo experiments clearly showed that 
immunoneutralization of MIF protects from the development of otherwise lethal 
Gram-negative infection (Calandra, Echtenacher et al. 2000).  
Studies with Salmonella typhimurium (Koebernick, Grode et al. 2002) on the other 
hand revealed that MIF-/- mice possessed a weakened Th1 response and incomplete 
macrophage activation, which led to hindered killing of intracellular S. typhimurium.  
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MIF release by macrophages also is induced by Gram-positive exotoxins, such as 
staphylococcal and streptococcal exotoxins.  Interestingly, MIF appears to be an 
indicator of patient outcome during septic shock.  High MIF levels have been a 
symptom of impending, fatal septic shock whereas lower concentrations are 
correlated with a high patient survival rate (Bozza, Gomes et al. 2004).  New 
treatment possibilities exist for septic shock patients as MIF neutralization has a larger 
therapeutic window for its administration than either anti-TNF or anti-IL-1 therapies 
(Abraham 1999).  Experiments with Mycobacterium tuberculosis showed that MIF 
neutralization in macrophages advances bacterial growth, whereas treatment with MIF 
leads to growth inhibition (Oddo, Calandra et al. 2005).  One could argue that MIF is 
essential for host defenses against infections; however, elevated MIF levels are 
dangerous and harmful as seen in chronic inflammatory diseases that are linked to 
development of cancer.  MIF is expressed in different human tumors at levels that 
may correlate with tumor aggressiveness (Tomiyasu, Yoshino et al. 2002).  
Several primitive eukaryotes encode MIF-like genes that show remarkable similarity 
to their mammalian counterparts, such as the human parasitic nematodes, Brugia 
malayi (Pastrana, Raghavan et al. 1998) and Ancylostoma ceylonicum (Cho, Jones et 
al. 2007).  The tick vector responsible for the transmission of anaplasmosis, 
Amblyomma americanum, produces an MIF ortholog that is expressed in the salivary 
gland (Jaworski, Jasinskas et al. 2001).  MIF-like proteins also have been reported 
recently in pathogenic species of Eimeria (Miska, Fetterer et al. 2007), Trichinella 
(Wu, Boonmars et al. 2003), and Plasmodium (Augustijn, Kleemann et al. 2007; 
Cordery, Kishore et al. 2007); whether these proteins play a role in parasite-host 
interactions has not been determined.  
 
1.4.10 Mammalian MIF and L. major infection 
MIF is not only involved in the recruitment of pro-inflammatory cells during infection 
but also in the regulation of their microbicidal activities.  
Juttner et al. showed that MIF affected Leishmania-infected macrophages by reducing 
the number of parasites in a dose-dependent manner (Juttner, Bernhagen et al. 1998).  
This effect was particularly notable late after infection, between 72 and 96 hours.  The 
simultaneous addition of IFN-γ together with MIF resulted in intensified macrophage 
activation.  One might argue that MIF and IFN-γ had a synergistic effect on these 
cells, but the work of Juttner et al. showed that they acted independently of each 
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other.  The leishmanicidal effect of MIF is induced by TNF-α macrophage activation 
and macrophage production of endogenous NO.  The cytokines IL-10 and IL-13 
(secreted by Th2 cells), in addition to TGF-β (secreted by macrophages), have been 
shown to impair the intracellular killing of Leishmania in vitro (Doherty, Kastelein et 
al. 1993; Vieth, Will et al. 1994; Barral, Teixeira et al. 1995; Juttner, Bernhagen et al. 
1998) by inhibiting the production of reactive nitrogen intermediates by IFN-γ-
activated macrophages .  Of note, lymph nodes draining the site of infection showed 
an up-regulation of MIF mRNA compared with the cytokines IL-12 (p35), IL-12 
(p40), IL-10, IL-1α, and IL-1β mRNA (Juttner, Bernhagen et al. 1998).  With the 
discovery of MIF functioning as a noncognate CXCR ligand (Bernhagen, Krohn et al. 
2007), its chemokine-like functions in inflammatory monocyte and T cell recruitment 
in respect to L. major infections probably will be needed to be interpreted from 
another perspective. 
In conclusion, MIF mRNA and protein expression both become up-regulated after L. 
major infection and contribute to the struggle of the host against the parasite. 
 
1.4.11 Mouse models 
Human and mouse MIF share 88% DNA sequence identity (Weiser, Temple et al. 
1989; Bozza, Kolakowski et al. 1995); therefore, it is customary to use mouse models 
in MIF research studies.  
The mouse genome consists of 19 autosomes plus 2 sex chromosomes with the MIF 
gene located in the middle of chromosome 10.  The mouse MIF gene consists of 3 
exons, separated by 2 introns of 201 and 144 base pairs, spanning 0.67 kb of the 
genome (Bozza, Kolakowski et al. 1995).  The mouse MIF gene maps to the middle 
region of chromosome 10; however, pseudogenes were discovered, with three 
mapping to chromosomes 1, 9, and 17.  These pseudogenes are highly homologous to 
mouse MIF but contain a variable number of mutations that would produce either 
truncated or mutated MIF-like proteins.  The pseudogenes are assumed to have 
evolved from retrotranspositional events as they display characteristic features of 
retrotransposed pseudogenes, including a lack of introns and the presence of a 
poly(A) tail in both the 3’ and 5’-untranslated regions (Bozza, Kolakowski et al. 
1995).  In the immediate 5’-flanking region of mouse MIF, the classical consensus 
TATA box is lacking as it is for human MIF. 
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To study the role of endogenous MIF, MIF-/- mice in a C57BL/6 × 129/Sv mice 
background were produced in 1999 by Bozza et al. (Bozza, Satoskar et al. 1999).  The 
difference between wild-type and MIF-/- mice with respect to L. major infections was 
studied in 2001 by Satoskar et al. (Satoskar, Bozza et al. 2001).  Infected L. major 
MIF-/- mice were susceptible to leishmaniasis and showed significantly larger lesions 
and greater parasitic burdens than MIF+/+ mice.  Satoskar et al. showed that this 
observation was due to impaired macrophage leishmanicidal activity rather than to an 
imbalance of Th1/Th2 responses.  As discussed above, the protective role of MIF in 
murine leishmaniasis can be attributed to its ability to induce macrophage NO 
production through IFN-γ.  Resting macrophages were tested for their leishmanicidal 
activity after IFN-γ stimulation.  Seventy-two hours after stimulation with IFN-γ, a 
significant difference between the parasite killing levels of MIF+/+ and MIF-/- mice 
was observed.  In the course of these studies, this result was attributed to lower O2- 
levels and NO production in MIF-/- mice.  Therefore, MIF is believed to play a 
significant role in the production of pro-inflammatory cytokines and anti-parasital 
agents to fight L. major infection. 
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2 Specific Aims  
Parasites must overcome external defenses to gain host entry, but by doing so, they 
must escape the powerful defense mechanisms of the host immune system.  One way 
to overcome the host defense system is to interfere with host cytokines.  Given the 
importance of cytokines in both natural and adaptive immunity, it is not surprising 
that parasites often interfere with cytokine function.  Parasites have been shown to 
possess genes that encode molecules that are virtually identical to host genes; they are 
called ‘orthologs’.  Macrophages are an important component of the host first line of 
defense system in the response to pathogenic infections.  Infection of a macrophage 
leads to the induction of numerous cellular genes, several of which encode cytokines 
that stimulate inflammatory responses and resistance to pathogens.  Hence, the control 
of Leishmania infection requires activation of macrophages that in turn leads to their 
leishmanicidal activity.  Leishmania parasites have developed strategies to escape 
host immune defenses and to survive in their hosts. 
We hypothesized that by possessing orthologs of human MIF, L. major has found a 
way to escape the host immune system, attack it, and spread infection, causing a 
dreadful disease in both humans and animals.  The very first goal of this research was 
therefore to confirm the expression of L. major MIF in vivo.  The next goal was to 
functionally characterize the identified ortholog, Lm1740MIF, which shares a 22% 
sequence identity with human MIF.  While host MIF appears to play an important role 
in the immune response against infections, there is no information about the role of L. 
major MIF during either infection or with respect to immune evasion mechanisms and 
in innate immunity.  The identification of the interaction between L. major MIF and 
macrophages will allow further studies of whether L. major MIF affects signal 
transduction.  Therefore, an additional goal of this thesis was to study and 
characterize the interaction of MIF with the macrophage surface receptor CD74.  
During this work, L. major MIF was discovered to interact functionally with the MIF 
receptor, CD74.  Since interactions between MIF and CD74 are known to lead to the 
induction of signal transduction processes, the next major aim was to investigate 
whether the interaction of L. major MIF with CD74 affected either ERK1/2 or p53 
activity, which may facilitate the intracellular persistence of L. major  in 
macrophages.  
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3 Materials and Methods 
3.1 Materials  
 
3.1.1 Mice 
Mice (BALB/c, C3H/HeJ, and C3H/HeN) were purchased from Charles River 
Laboratories (Wilmington, MA). BALB/c mice deficient in the MIF receptor CD74 
(CD74-KO) were originally provided by Dr. Idit Shachar (Weizmann Institute, 
Rehovot, Israel) (Starlets, Gore et al. 2006). C3H/HeJ mice are defective in their 
lipopopolysaccharide response allele TLR4. 
 
3.1.2 Material lists 
 
Source of supply Internet adresse  Headquarters 
   
American 
Bioanalytical 
www.americanbio.com Natick, MA 01760, 
USA 
American National 
Can™ 
www.2spi.com West Chester, PA 
19381, USA 
Amersham 
Biosciences 
www.amershambiosciences.com Piscataway, NJ 08855, 
USA 
BD Biosciences www.bdbiosciences.com Franklin Lakes, NJ 
07417, USA 
Beckman Coulter™ www.beckmancoulter.com Fullerton, CA 92834, 
USA 
Bio101 siehe Qbiogene  
Biocompare www.biocompare.com South San Francisco, 
CA 94080, USA 
BioRad www.bio-rad.com Hercules, CA 94547, 
USA 
Carnation www.carnation.ca  
Cell Signalling www.cellsignal.com Danvers, MA 01923 
Corning Incorporated www.corning.com Big Flats, NY 14814, 
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USA 
Cryostar Industries, 
Inc. 
www.sanyobiomedical.com Bensenville, IL 60106, 
USA 
Denville www.denvillescientific.com Metuchen, NJ 08840, 
USA 
DIFCO www.difco.com  Franklin Lakes, NJ 
07417, USA 
DotScientific Inc. www.dotscientific.com Burton, MI 48519, 
USA 
DuPont® www.dupont.com Wilmington, DE 
19898, USA 
EmbiTec www.embitec.com Carlsbad, CA 92008, 
USA 
Eppendorf AG www.eppendorf.com 22339 Hamburg, 
Germany 
Fisher Scientific www.thermofisher.com Waltham, MA 02454, 
USA 
Frigidair Commercial www.biobank.co.kr Conway,AR 72032, 
USA 
General Electrics GE www.ge.com  
GE Healthcare www.gehealthcare.com/lifesciences Piscataway, NJ 08855,
USA 
GIBCO® siehe Invitrogen  
GIBCO BRL®  siehe Invitrogen  
Hausser Scientific www.hausserscientific.com Horsham, PA 19044, 
USA 
Hoefer Inc.  www.hoeferinc.com San Francisco, CA 
94107, USA 
Invitrogen™ www.invitrogen.com Carlsbad, CA 92008, 
USA 
J.T.Baker www.jtbaker.com Phillipsburg, NJ 
08865, USA 
Kendro www.kendro.com Asheville, NC 28806, 
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USA 
Kodak www.kodak.com  
Kysor Panel Systems www.kysorpanel.com Fort Worth, TX 
76137, USA 
Leica www.leica-microsystems.com Bannockburn, IL 
60015, USA 
Millipore www.millipore.com Billerica, MA 01821, 
USA 
Micro-Tech Optical 
NE Inc. 
MT01@MSN.COM Bloomfield, CT 6002, 
USA 
MJ Research  www.mjr.com Waltham, MA 02451, 
USA 
Ohaus Corporation www.ohaus.com Pine Brook, NJ 07058, 
USA 
Pierce www.piercenet.com Rockford, IL 61105, 
USA 
Qbiogene www.qbiogene.com Irvine, CA 92618, 
USA 
Roche Diagnostics 
Corporation 
www.roche-applied-science.com Indianapolis, IN 
46250, USA 
Santa Cruz 
Biotechnology 
www.scbt.com Santa Cruz, CA. 
95060, USA 
Scotsman www.scotsman-ice.com Vernon Hills, IL 
60061, USA 
Sigma-Aldrich Co. www.sigmaaldrich.com St.Louis, MO 63103, 
USA 
Steris® www.steris.com Mentor, OH 44060, 
USA 
The Baker Company www.bakerco.com Sanford, ME 04073, 
USA 
Thermo Scientific www.thermo.com Waltham, MA 
02454,USA 
USA Scientific, Inc. www.usascientific.com Ocala, FL 34478, USA 
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VWR Scientific  www.vwrsp.com West Chester, PA 
19380, USA 
        
Equipment/instruments Source of supply 
  
Autoradiography cassettes Fisher Scientific  
Centrifuge 5415C Eppendorf 
+ 37ºC chamber Kysor Panel Systems 
Digi-Block™ Jr. Laboratory Devices 
DU® 530 Life Science UV/VIS 
Spectrophotometer 
Beckman Coulter™ 
Microscope, Leica DM1RB Leica 
ELISA-Spectramax PLUS 384 Molecular Devices 
- 20ºC freezer Frigidair Commercial 
+ 4ºC fridge National Brokar Inc. 
+ 22°C incubator Fisher Scientific 
+37°C incubator Kysor Panel Systems 
GelDoc 1000  BioRad 
HeraCell 240 Kendro 
Ice machine Scotsman 
X-Omat 2000A processor Kodak 
MacroVue UV-25 Hoefer 
Mini Cycler™ PTC-150 MJ Research 
MR5000 Dynatech 
Olympus CK2 microscope Micro-Tech Optical (NE), Inc. 
Peltier Thermal Cycler PTC-100 BioRad 
PowerPac 300 BioRad 
Programmable thermal controller MJ Research 
Run One™ electrophoresis cell EmbiTec 
Scale Scout™ Pro SP402   Ohaus Corporation 
Scientific Prevacuum Sterilizer SV-120 Steris 
Sorvall® RC-5B refrigerated superspeed 
centrifuge 
DuPont Instruments 
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SterilGard® III Advance The Baker Company 
Turntable microwave oven  General Electrics 
Vortex-Genie 2™ VWR Scientific 
XCell II™  Invitrogen 
 
Materials Source of supply 
  
2 ml aspirating pipet   BD Labware Falcon® 
1-20 µl bevelled filter tips    USA Scientific 
Blotting paper, 703 VWR 
BlueMax™ 50 ml polypropylene conical 
tube, 30 x 115 mm style, nonpyrogenic 
BD Labware Falcon® 
BlueMax™ Jr. 15 ml polypropylene 
conical tube   
BD Labware Falcon® 
Cell culture Flask, 25cm2, sterile, non-
pyrogenic, tissue culture treated, canted 
neck 
Corning Incorporated 
Cellcounter Hausser Scientific 
Cell scraper BD Labware 
Costar stripette 5 ml, non pyrogenic, 
serological pipet  
Corning Incorporated 
Costar stripette 10 ml, non pyrogenic, 
serological pipet  
Corning Incorporated 
Costar stripette 25 ml, non pyrogenic, 
serological pipet  
Corning Incorporated 
500 ml filter system, 0.22 µm cellulose 
acetate, sterilizing, low protein binding 
membrane, non-pyrogenic, polystyrene 
Corning Incorporated 
0.1-10 µl filter tips    USA Scientific 
Immobilion-P transfer membrane; pore 
size: 0.45 µm 
Millipore 
Microseal® ‘B’ Film, PCR Sealers™ BioRad 
Multiplate® PCR Plates™, 96-well, clear BioRad 
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1.5 ml natural microcentrifuge tubes, 
Rnase, Dnase, DNA and pyrogen free 
USA Scientific 
Parafilm     American National Can™ 
PetriDish, 100x15mm BD Labware Falcon® 
Pipette Tips, Universal Fit, 1-200 µl, tip 
round 
DotScientific Inc. 
200 µl precision barrier tips   Denville 
Scientific imaging film Kodak 
Tissue culture dish Falcon®Tissue 
Culture treated by vacuum gas plasma, 
100 x 20 mm style, polystyrene, non-
pyrogenic 
BD Labware Falcon® 
1000 µl ultra sharp filter tips Denville 
0.2 ml thin-wall tubes with attached 
domed caps   
BioRad 
 
Commercially available buffers and 
solutions 
source of supply 
  
Distilled Water 0.1 micron filtered  GIBCO® 
DMEM, 1 x 0.1 micron filtered, high 
glucose with L-glutamine, with 
pyridoxine  
Hydrochloride, without sodium pyruvat 
GIBCO® 
Dulbecco’s PBS, 1 x 0.1 micron filtered, 
without calciumchloride, without 
magnesium chloride 
GIBCO® 
ECL™Western Blotting Detection 
reagents 
GE Healthcare 
Ethidium bromide solution 10m (10 g/ml) Invitrogen 
FBS    GIBCO® 
Glycerol (synthetic) C3H8O3 500 ml ultra 
pure ACS/USP grad 
American Bioanalytical 
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Methanol  J.T. Baker 
NuPage® antioxidant Invitrogen 
NuPage® LDS sample buffer 4x Invitrogen 
NuPage® MES SDS running buffer (20x) Invitrogen 
NuPage® MOPS SDS running buffer 
(20x) 
Invitrogen 
NuPage® transfer buffer (20x) Invitrogen 
Percoll Sigma 
Restore™ Western Blot stripping buffer ThermoScientific 
RPMI 1640 (1x) ; with L-glutamine GIBCO® 
Schneider’s Insect Medium with L-
glutamine without calcium chloride and 
sodium bicarbonate 
Sigma-Aldrich 
Thioglycollate Sigma-Aldrich 
Tris-HCl Sigma-Aldrich 
Trizol Gibco 
Tween-20 Pierce 
Ultra Pure 10 x TAE buffer 
concentration of 10 x solution:  
400 mM Tris acetate and 10 mM EDTA 
 
Invitrogen 
Versene 1:5000 (1x) contains 0.2 g/l 
EDTA·4Na in Phosphate-buffered saline 
GIBCO® 
Water, RNase free, Endotoxin tested, 
treated with DEPC to eliminate RNase 
American Bioanalytical 
 
Chemicals, enzymes and molecular 
biology materials and reagents  
Source of supply 
  
Agarose GPG/LE    American Bioanalytical 
anti-rabbit IgG, HRP-linked Antibody Cell Signaling 
Blotting Greade Blocker Non-Fat Dry 
Milk 
BioRad 
BSA BioRad 
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Cell Death Detection ELISAPLUS  Roche 
Dithiothreitol (DTT) Sigma-Aldrich 
100bp DNA ladder 50 µg (0.1 µg/µl) Invitrogen 
EDTA Biocompare 
EtBr Sigma-Aldrich 
Gene Clean III kit  Bio101 
Gentamicin Invitrogen 
NaCl J.T.Baker 
non-fat dry milk Carnation 
NuPage® 4-12% Bis-Tris Gel, 
1.0x10well 
Invitrogen 
NuPage® 4-12% Bis-Tris Gel, 
1.0x12well 
Invitrogen 
penicillin/streptomycin GIBCO® 
p44/42 MAP kinase antibody Santa Cruz Biotechnology 
phopho- p44/42 MAP kinase antibody Cell Signaling 
p53 antibody Cell Signaling 
phospho- p53 antibody Cell Signaling 
PBS BD Biosciences 
PCR-Supermix Invitrogen 
Methanol J.T.Baker 
SDS-Polyacrylamid gel Invitrogen 
SeeBlue® Plus2 prestained standard (1x) Invitrogen 
SNP    Amersham Biosciences 
 
Buffer and solutions Composition 
  
100 bp ladder 10 µl 100 bp stock solution, 50 µl 6 x 
loading buffer, 440 µl 0.5 x TAE + EtBr  
1 kb ladder 10 µl 1 kb stock solution, 50 µl 6 x 
loading buffer, 440 µl 0.5 x TAE + EtBr  
6 x loading buffer 0.25 % Bromphenolblue, 0.25 % Xylene 
Cyanole FF, 30 % Glycerol 
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Electrophoresis buffer 50 ml TAE, 50 µl EtBr, 950 ml dH2O 
Lysis buffer 20 mM HEPES, pH 7.4; 50 mM β-
Glycerolphosphate ; 2 mM EGTA (Acetic 
Acid) ; 1 mM DTT (Dithiothreitol) ; 10 
mM NaF ; 1 mM NaVO4 ; 1% Triton x-
100 ; 10% Glycerol 
MES 50 ml MES (20X); 950 ml deionized 
water 
MOPS 50 ml MOPS (20X); 950 ml deionized 
water 
Schneider’s complete media 30 ml FCS, 4 ml L-glutamine, 166 ml 
Schneiders, 120 µl Gentamycin 
TE buffer 10 mM Tris HCl, pH 7.4; 1 mM EDTA, 
pH 8.0 
TBST 20 mM Tris-HCl, pH7.4; 150 mM NaCl; 
0.05% Tween-20; 950 ml dH2O 
1X NuPage® transfer buffer 50ml 20X NuPage® transfer buffer; 100 
ml methanol; 850ml deionized water 
 
Primers 
 
All primers were ordered from the W.M.Keck Oligonucleotide Synthesis Facility at 
Yale University, New Haven, CT, USA. 
 
Primer name Primer sequence Used for 
L1740 forward 5’-ATG CCG GTC ATT 
CAA ACG-3’ 
amplification of 
LmjF33.1740 DNA 
L1740 backward 5’-TTA GAA GTT TGT 
GCC ATT CC-3’ 
amplification of 
LmjF33.1740 DNA 
L1740 backward short 5’-CTC TGG TTT GCC 
GAG TAC A-3 
Amplification of  
LmjF33.1740 DNA for 
qPCR analysis 
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L1750 forward 5’-ATG CCG TTT CTG 
CAG AC-3’ 
amplification of 
LmjF33.1750 DNA 
L1750 backward 5’-TCA AAA GTT AGT 
GCC GTT-3’ 
amplification of 
LmjF33.1750 DNA 
L1750 backward short 5’-AGT CAT CAC GAA 
GTC CTC-3’ 
Amplification of  
LmjF33.1750 DNA for 
qPCR analysis 
ADP/ATP carrier 
forward 
5’-ATC TCA TAC CCG 
CTG GAC AC-3’ 
amplification of the 
ADP/ATP carrier as a 
housekeeping gene for 
qPCR analysis 
ADP/ATP carrier 
backward 
5’-TCA AGC GAG TTG 
CGG TAG TT-3’ 
amplification of the 
ADP/ATP carrier as a 
housekeeping gene for 
qPCR analysis 
rRNA45 forward 5’-CCT ACC ATG CCG 
TGT CCT TCT A-3’ 
amplification of rRNA45 
as a housekeeping gene 
for qPCR analysis 
rRNA45 backward 5’-AAC GAC CCC TGC 
AGC AAT AC-3’ 
amplification of the 
rRNA45 as a 
housekeeping gene for 
qPCR analysis 
 
Methods 
3.1.3 Sequence and phylogenetic analyses 
Phylogenetic analyses were carried out using sequences from the ClustalW multiple 
alignment output using the Neighbor-Joining method (Saitou and Nei 1987) via the 
MEGA3.1 (Kumar, Tamura et al. 2004) interface  with the following settings for 
DNA phylogenetic analysis: pairwise alignement parameters: gap opening penalty 15; 
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gap extension penalty 6.66; multiple alignment: gap opening penalty 15; gap 
extension penalty 6.66; delay divergent cutoff 30%; DNA transition weight 30%; 
weight matrix IUB with 5000 bootstrap replicates. For protein phylogenetic analysis, 
the following settings were chosen: pair-wise alignment parameters: gap opening 
penalty 10; gap extension penalty 0.1; multiple alignment: gap opening penalty 10; 
gap extension penalty 0.2; Gonnet protein weight matrix and delay divergent cutoff 
30%.  To compare identity, the Expert Protein Analysis System (ExPASy) proteomics 
server of the Swiss Institute of Bioinformatics was employed.  The interface T-Coffee 
(Poirot, O'Toole et al. 2003) was used for sequence alignment and the residues are 
numbered in accordance with the alignment; gaps are counted. 
 
3.1.4 Mice 
All mice were used at 6-8 weeks of age, and experiments were performed in 
accordance with the Yale University’s IACUC (Institutional Animal Care and Use 
Committee). 
 
3.1.5 Parasite and cell cultures  
Bone marrow macrophages (BMMs) were harvested from mouse femurs and cultured 
for 4 days in 10 cm plates with complete medium containing RPMI 1640 (GibcoBRL, 
Gaithersburg MD), 20% fetal bovine serum (FBS), 30% L929-conditioned medium 
(LCM), and 1% penicillin/streptomycin. On day 5, cells were re-plated at a density of 
4x106/ml and treated according to the intended experiments. Peritoneal exudate cells 
were obtained from mice that were injected 3-4 days previously with 2 ml of 4% 
sterile thioglycollate broth (Calandra, Bernhagen et al. 1994). Leishmania major 
(MHOM/IL/79/LRC-L251) (Beverley, Ismach et al. 1987) promastigotes were 
cultured at 23ºC in complete Schneider's medium supplemented with 20% heat-
inactivated FBS and gentamicin (10 μg/ml). 
 
3.1.6 Reverse transcriptase-PCR analyses and quantitative PCR 
Total RNA from L. major was isolated from procyclic and metacyclic cultures, and 
from amastigotes isolated from homogenized, infected mouse lymph nodes using the 
Trizol reagent (Invitrogen).  As the presence of dead or dying organisms might lead to 
a mixture of procyclic/metacyclic cultures and contribute to false data, live metacyclic 
organisms were separated from the cellular debris present in stationary-phase cultures 
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via a Percoll step gradient.  The gradient consisted of 90% Percoll in phosphate-
buffered saline (PBS) that was overlaid with parasites that had been resuspended in 
45% Percoll (in PBS); the gradient was then overlaid with solutions of 30% and 20% 
Percoll (in PBS) and centrifuged at 6000 rpm for 45 min at 4 °C.  Live parasites were 
isolated at the 20–30% interface.  After isolation from the Percoll gradient, parasites 
were washed in 2 ml of 1× PBS and centrifuged at 1,500 rpm for 15 min.  The Trizol 
reagent was used subsequently for the metacyclic pellet.  For gene expression 
quantification, the two-step quantitative, reverse-transcriptase PCR method was 
applied.  First, the isolated total RNA was reverse-transcribed using the AccuScript™ 
Kit from Stratagene according to the manufacturer’s instructions.  The principle for 
reverse-transcriptase PCR involves the extraction of all tissue or cellular RNA under 
study and their transcription in vitro into single-stranded cDNAs.  The cDNA 
molecules obtained then serve as a template for PCR using specific primers.  PCR of 
the cDNA products consisted 32 cycles of a denaturation step (94 ºC, 1 min), an 
annealing step (50 ºC, 2 min), and an elongation step (72 ºC, 3 min).  For the last 
cycle, the elongation step was extended to 10 min at 72 ºC.  The Taq DNA 
polymerase was used for the amplification steps.  Specific primers used are listed in 
the Material and Methods, Primers.  PCR products were purified from unspecific 
products on a 2% agarose gel.  The bands at the specific fragment sizes were excised 
and purified with the Gene Clean III Kit.  An aliquot of the resulting cDNA was used 
as the template for quantitative PCR (qPCR).   
To evaluate the quantity of RNA present in the different developmental stages of L. 
major, qPCR was performed using SYBR Green, which intercalates into the DNA 
helix.  The fluorescence increases as the amount of the PCR product increases and 
was quantified after each completed PCR cycle.  The results are displayed as relative 
expression values of the gene of interest (GOI).  Therefore, the results are related to 
the internal controls (control genes or housekeeping genes) that are present at constant 
expression levels in all samples. 
Both the L. major ADP/ATP carrier (LmjF19.0210) (Leifso, Cohen-Freue et al. 2007) 
and rRNA45  (CC144545) (Ouakad, Bahi-Jaber et al. 2007) transcripts served as 
internal controls.  The amplification primers were Lm1740FWD: 5’-ATG CCG GTC 
ATT CAA ACG-3’; Lm1740BWD2: 5’-CTC TGG TTT GCC GAG TAC A-3’; 
Lm1750 FWD: 5’-ATG CCG TTT CTG CAG AC-3’; Lm1750BWD2: 5’-AGT CAT 
CAC GAA GTC CTC-3’; CarrierFWD: 5’-ATC TCA TAC CCG CTG GAC AC-3’; 
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CarrierBWD: 5’-TCA AGC GAG TTG CGG TAG TT-3’; rRNA45FWD: 5’-CCT 
ACC ATG CCG TGT CCT TCT A-3’; and rRNA45BWD: 5’-AAC GAC CCC TGC 
AGC AAT AC-3’.  qPCR was performed using a DNA SYBR Green kit according to 
the manufacturer's instructions (Roche).  Amplification of both Lm1740MIF and 
Lm1750MIF was carried out for 3 min at 95 °C, and 30 sec at 95 °C followed by 30 
sec at 60 °C for 40 cycles.  Amplification of both the ADP/ATP carrier and rRNA45 
was carried out for 3 min at 95 °C, and 30 sec at 95 °C followed by 30 sec at 62 °C 
for 40 cycles.  The linearity and optimization of the assays were ensured by 
performing serial dilutions of the templates for each primer set.  The results were used 
to generate standard curves.  Normalization of real-time qPCR data was performed by 
calculating the arithmetic mean of the internal control genes using the qgene software  
(Muller, Janovjak et al. 2002).  
 
3.1.7 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method used to separate DNA molecules by size.  
Samples that consisted of 10 µl DNA and 2 µl loading buffer (6×) were loaded onto 
2% agarose gels containing 10 mg/ml ethidium bromide (EtBr) and run at 100 V in 
250 ml electrophoresis buffer.  The loading buffer increases the density of the sample, 
making it easier to pipette into the agarose gel slots.  Gels with positive results were 
photographed under 260-nm UV light; excision of DNA bands was performed under 
312-nm UV light. 
 
3.1.8 Purification of DNA products after PCR 
After electrophoresis, the PCR products were purified and isolated with the Gene 
Clean III Kit (Bio101) according to the manufacturer’s instructions.  Purified DNA 
was eluted in 40 µl dH2O and stored at -20 °C.  
 
3.1.9 DNA and RNA concentration 
Concentration and quality of DNA and RNA samples were measured with a UV 
spectrophotometer.  After dilution in water, DNA and RNA concentrations were 
measured at a wavelength of 260 nm.  DNA or RNA concentrations were calculated 
using following formula: 
c (µg/ml) = OD260 * V * F 
where c = concentration of the starting material  
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V = dilution factor 
F = multiplication factor = for dsDNA: 50; for RNA: 40 
The ratio of OD260/OD280 provides an estimate of the purity of the sample.  
 
3.1.10 MIF receptor binding studies 
The real-time binding interaction of Lm1740MIF with CD74 was measured by 
surface plasmon resonance using a BIAcore 2000 optical biosensor (BIAcore AB, 
Piscataway, NJ) as previously described (Leng, Metz et al. 2003). The CM5 sensor 
chips and the BIA Evaluation software were from GE Healthcare (Buckinghamshire, 
UK). The MIF receptor ectodomain (sCD7473-232) was immobilized according to the 
manufacturer’s instructions using the Biacore Amine Coupling Kit.  Briefly, sCD7473-
232 was diluted in 10mM sodium acetate (pH 5.2) at a concentration of 1 μM. 50 μl of 
an N-hyrdoxysuccinimide (NHS) and N-ethyl-N-(dimethyaminopropyl)-carbodiimide 
(EDC) mixture was injected at a speed of 2 μl /min for 25 min, followed by injection 
of 50 μl of 1 μM of purified sCD7473-232.  Once the surface plasmon resonance 
reached 10,000 U, the injection was stopped and the active amine sites blocked with 
35 μl of 1 M ethanolamine (pH 8.5). The immobilized CM5 chip was washed 
overnight with 1xPBS at 20 μl/min. The derived sensor chips were washed and 
equilibrated in HEPES or PBS pH 8.0 (20 μl/min), and the ligand (Lm1740MIF) was 
introduced at five serial dilutions in BIAcore buffer (1 mM DTT, 2.5 mM MgCl2, 20 
mM HEPES, 1 mM EDTA, 150 mM NaCl, 0.005% P20) in 60-100 μl injection 
volumes at a flow rate of 20 μl/min.  Binding was measured at 25oC for 5 min, 
followed by 15 min of dissociation.  One min of sensor chip regeneration was then 
performed with 1 M NaCl/50mM NaOH.  The whole process was repeated 3 times for 
each sample dilution.  Sensorgram response data was analyzed in the BIA evaluation 
kinetics package and the equilibrium binding constants calculated.  
 
3.1.11 Protein concentration 
Protein concentration was determined using the Bradford method (Bradford 1976).  A 
standard curve was generated using bovine serum albumin (BSA).  Absorption was 
measured at 595 nm with a spectrophotometer. 
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3.1.12 Western blotting 
Western blotting is a technique used to detect a specific protein in a complex mixture 
based on its molecular weight and ability to bind to specific antibodies.  Western 
blotting can also be used to measure the relative amounts of the protein present in 
different samples as described by Laemmli (Laemmli 1970).  The proteins are first 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to a membrane such as polyvinylidene difluoride (PVDF), and 
incubated with a primary antibody raised against a specific antigen, the protein of 
interest.  The primary antibody is then incubated with a secondary antibody, which is 
conjugated to a reagent for detection, such as horseradish peroxidase.  Because the 
strength of the Western blot signal depends on two factors, that is, the affinity of the 
antibody for the antigen and the concentration of antigen, the described technique is 
not considered a quantitative measurement of antigen concentration. 
Cell lysates from bone marrow-derived macrophages (BMMs) were lysed with lysis 
buffer and mixed with reducing 4× loading buffer and boiled for 10 min at 100 °C.  
After the samples were cooled to room temperature, 50 mM dithiothreitol (DTT) was 
added.  Samples were loaded onto mini-gels (NuPage®, 4-12%, Invitrogen) and 
separated at 120 V for one hour.  SDS-PAGE was performed at room temperature in 
either MES or MOPS buffer.  After separation, proteins were transferred to a PVDF 
membrane.  The wet protein-transfer method was performed using Invitrogen’s XCell 
II™ Blot Module at 30 V for 1 hour at room temperature.  The blots were 
subsequently blocked in 5% non-fat dry milk in TBS/0.1% Tween-20 (TBST) for 30 
min and then washed three times with TBST buffer for 10 min each wash.  The 
membranes were incubated at room temperature for 2 hours or overnight at 4 °C with 
different primary antibodies.  After washing the membranes with TBST buffer as 
described above, the membranes were incubated with horseradish peroxidase-linked 
secondary antibodies for 1 hour at room temperature.  Blots were then washed three 
times for 10 min each in TBST.  The horseradish peroxidase-linked secondary 
antibody is used in conjunction with an enhanced chemiluminescence reagent 
(Amersham Biosciences), and the reaction product produces luminescence 
proportional to the amount of protein.  Photographic film (Kodak) was placed against 
the PVDF membrane inside an autoradiography cassette, and exposure to the light 
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emitted by the reaction products created an image of the antibodies bound to the blot.  
Films were developed using an X-Omat 2000A. 
 
3.1.13 ELISA (enzyme-linked immunosorbent assay) 
The specific and highly sensitive ELISA method can be used as a quantitative 
measurement of proteins in solution.  
A specific monoclonal antibody that binds the cytokine of interest is coated on a 
microtiter plate.  The sample and standards are then loaded onto the microtiter plate.  
A second monoclonal antibody that binds a different epitope on the cytokine is 
applied and used for detection purposes.  Any unbound reagents are washed away.  
The secondary antibody is labeled with biotin, which allows subsequent binding of a 
streptavidin-conjugated enzyme.  Samples are incubated with the peroxidase 
substrate, 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid), (ABTS).  
Horseradish peroxidase catalyzes the conversion of ABTS in the presence of 
hydrogen peroxide into a green end-product.  Its absorbance maximum of 405 nm can 
easily be detected with a spectrophotometer.  The color of the reaction is proportional 
to the amount of bound cytokine.  The concentration of cytokine is determined from 
comparison with a standard curve.  The sensitivity of the ELISA depends primarily on 
the affinity of the antibodies for the protein.  The detection limits for cytokine 
ELISAs are commonly in the lower picogram/ml range. 
 
3.1.13.1 Cell Death Detection ELISAPLUS 
BMMs from wild-type and CD74-KO mice were incubated with either Lm1740MIF 
or mMIF and SNP (NO donor), an inducer of apoptosis.  After incubation, the cells 
were precipitated by centrifugation and the supernatant, which contains DNA from 
necrotic cells, was discarded.  Cells were resuspended and incubated in lysis buffer.  
After lysis, intact nuclei were precipitated by centrifugation.  Aliquots of the 
supernatant were transferred to a streptavidin-conjugated microtiter plate.  
Nucleosomes in the supernatant were labeled with immunoreagent, a mixture of anti-
histone-biotin and anti-DNA-horseradish peroxidase.  The antibody-nucleosome 
complexes bound to the streptavidin through the anti-histone-biotin.  Cell components 
that were not immunoreactive were removed by washing three times with incubation 
buffer.  Samples were then incubated with the peroxidase substrate, ABTS. 
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3.1.14 Apoptosis studies   
BMMs were cultured for 5 days in 20-mm plates, treated with either murine MIF 
(Mitchell, Liao et al. 2002) or Lm1740MIF, and incubated overnight either with or 
without SNP.  Apoptosis was quantified by Cell Death Detection ELISAPLUS (Roche) 
for cytoplasmic histone-associated DNA fragments.  Cytoplasmic p53 content was 
analyzed by immunoblotting using a pair of anti-phospho-p53 (Ser15) and anti-p53 
antibodies according to the manufacturer’s instructions.  The secondary antibody was 
an anti-rabbit IgG antibody conjugated to horseradish peroxidase, and detection was 
by chemiluminescence.  The blots displayed are representative of stimulation studies 
that were performed at least in triplicate.  
3.1.15 Signal transduction studies  
Mouse BMMs and mouse thioglycollate-elicited peritoneal macrophages (4×106 per 
plate) were rendered quiescent by incubation in 0.1% FBS prior to stimulation with 
MIF for 2 hours (Mitchell, Metz et al. 1999).  Apoptosis was induced with SNP.  
Negative controls did not have cell death stimulated by SNP.  Cells were lysed in 
buffer containing 20 mM HEPES (pH 7.4), 50 mM β-glycerolphosphate, 2 mM 
EGTA, 1 mM DTT, 10 mM NaF, 1 mM NaVO4, 10% glycerol, 1% Triton X-100, and 
freshly added protease inhibitors (Complete, Mini, EDTA-free, Roche).  For 
immunoblotting, cell lysates were separated via 10% SDS-PAGE and transferred to 
PVDF Immobilon-P membranes.  Immunoblotting was carried out using antibodies 
directed against total ERK1/2 and phospho-ERK-1/2 according to the manufacturer’s 
instructions.  The secondary antibody was an anti-rabbit IgG antibody conjugated to 
horseradish peroxidase, and detection was by chemiluminescence.  The blots 
displayed are representative of stimulation studies that were performed at least in 
triplicate.  
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4 Results 
4.1 Sequence alignment and phylogenetic analyses  
Two genetic loci, Lm1740 and Lm1750, were identified on chromosome 33 in the 
recently sequenced Leishmania major genome (Ivens, Peacock et al. 2005) to have an 
open reading frame (342 bp) with 10–13% identity to the human MIF gene.  After 
comparison with other Leishmania and Typanosomatid genes (Landfear, Miller et al. 
1986), both a trypanosoma-consensus TATA box and a polyadenylation signal 
sequence were evident in the flanking regions of these loci (Fig. 8).  
 
 
 
 
Fig. 8.  Physical map of the Leishmania major chromosome-33 region encompassing 
nucleotides 804882–806078.  The two mif-related genes, Lm1740 (accession number Q4Q413) 
and Lm1750 (accession number Q4Q413), are shown together with consensus TATA boxes and 
polyadenylation signal sequences.   
 
The two putative L. major MIF orthologs (Lm1740MIF and Lm1750MIF) were 
predicted to encode a 112-amino acid protein after processing of the initiating 
methionine residue.  Similar to other MIF orthologs that have been described 
(Pastrana, Raghavan et al. 1998; Jaworski, Jasinskas et al. 2001; Augustijn, Kleemann 
et al. 2007; Cho, Jones et al. 2007; Cordery, Kishore et al. 2007) the Leishmania 
MIF-like genes do not contain an N-terminal secretory signal sequence. 
Phylogenetic analyses using the Neighbor-Joining method for both DNA and protein 
sequences produced similar results; results of these protein analyses are displayed in 
Fig. 9. 
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Fig. 9.  Phylogram of parasitic MIF protein sequences, including five mif-related proteins 
identified in L. major, L infantum, and L. braziliensis.  The sequence of Clostridium 
phytofermentas was used to resolve relationships among MIF-expressing parasites.  The 
percentages of replicate trees in which the associated taxa clustered together in the bootstrap test 
(5000 replicates) are shown next to the branches.  The evolutionary distances were computed 
using the Poisson correction method and are presented as the number of amino acid substitutions 
per site.  The gene accession numbers are as follows: L. infantum 2100 XM_001468253; L. 
infantum 2090 XM_001468252; L. braziliensis CAM40731; L. major1740 Q4Q413; L. 
major1750 Q4Q412; T. gondii DQ344450; E. acervulina DQ323516; E. tenella DQ323515; A. 
simplex EF165010; W. bancrofti AF040629; P. yoelli yoelli DQ494171; P. falciparum AY561832; 
P. chabaudi CAH75532; P. berghei CAH99597; T. trichuria AJ237770; T. spiralis AY050661; A. 
suum AB158366; E. histolytica XM_650516; A. ceylanicum EF410151; B. malayi (1) AF002699; 
B. malayi (2) AY004865; O. volvulus mif-1 AF384027; and O. volvulus mif-2 AF384028.    
 
 Gene duplication can account for paralogs within the same organism, and likely 
explains the origin of the two L. major and L. infantum MIF-related sequences.  
Lm1740MIF was 58–99% identical to MIF-like gene sequences from other 
Leishmania species and 22–31% identical to mammalian MIFs.  Except for certain 
branch rearrangements, few differences were observed between the topology of the 
MIF DNA and protein phylograms (data not shown).  
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An amino acid-sequence alignment of twelve selected members of the MIF protein 
family was prepared using the T-Coffee multiple sequence alignment program (Fig. 
10).  
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Fig. 10.  Amino acid-sequence alignment of selected MIF molecules constructed with the T-
Coffee program .  A line marked “consensus” is shown for each residue: “*” denotes complete 
conservation, “:” indicates conservation of both residue size and hydropathy, and “.” denotes 
conservation of either size or hydropathy.  The color code signifies the consistency between a 
multiple alignment and each pair of aligned residues.       : inconsistent bits, unlikely to be 
correctly aligned;              : bits correspond to the residues more likely to be correctly aligned 
(with red the highest reliable portion).  The consensus sequence indicates that the average 
reliability value for every residue column is provided.  Additional gene accession numbers are as 
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follows: A. americanum Q9GUA9; G. gallus Q02960; M. musculus P34884; H. sapiens Q6FHV0; 
M. mulatta Q6DN04; and S. scrofa Q069I4.  
 
 
These conserved cysteines, as well as the CXXC motif, are absent in the L. major 
sequences. The MIF N-terminal proline (Pro1) by contrast appears strictly conserved, 
with the exception of the grossly truncated Leishmania braziliensis sequence. 
Leishmania MIF does not exhibit the CXXC motif; however, it does have one of the 
“extended” TPOR requirements by containing the Phe of mammalian MIF at position 
-7 (the “extended” TPOR requirements of mammalian MIF are a Phe at position -7 
and a Leu at position -10 of its CXXC motif). 
 
4.2 Expression of Leishmania major MIF in vivo 
The expression of the Lm1740MIF and Lm1750MIF genes in vivo was confirmed by 
reverse transcriptase-PCR analysis of total RNA prepared from L. major 
promastigotes (strain MHOM/IL/79/LRC-L251,  (data not shown).  Quantitative PCR 
analysis (qPCR) of the three life stages of the L. major parasite revealed that procyclic 
parasites expressed more LmMIF than either metacyclic or amastigote parasites, the 
latter isolated from within the lymph nodes of infected mice (Fig. 11).  The 
differences in the expression levels of Lm1740MIF and Lm1750MIF were quantified 
using the qgene  software with respect to two “housekeeping” genes, rRNA45 and 
ADP/ATP carrier . 
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Fig. 11.  Lm1740MIF and Lm1750MIF mRNA expression.  Real-time qPCR analysis of total 
RNA from L. major procyclic and metacyclic parasites cultured in vitro, and from amastigotes 
present within the infected lymph nodes of mice.  Results are presented for Lm1740MIF and 
Lm1750MIF transcripts relative to the reference genes rRNA45 and ADP/ATP carrier.  All 
samples were run in triplicate.  The p values were calculated using the Student’s t test.  **p<0.01 
for procyclic versus either metacyclic or amastigote parasites.  *p<0.05 for procyclic versus either 
metacyclic or amastigote parasites. The values for p>0.05 are not displayed. 
 
4.3  Lm1740MIF binds to the MIF receptor CD74  
After demonstrating L. major MIF transcription, it was determined whether 
Lm1740MIF could influence host immunity by engaging the human MIF receptor, 
CD74.  To begin to achieve this goal, the equilibrium dissociation constant for 
Lm1740MIF binding to sCD74 (soluble CD74) was measured by surface plasmon 
resonance (BIAcore analysis), which measures real-time binding interactions by 
changes in the refractive index of a biospecific surface. BIAcore analysis revealed a 
Kd of 2.9×10-8 M for the binding between Lm1740MIF and sCD74 (Fig. 12). This 
contrasts with a previously determined Kd for the binding of human MIF with sCD74 
of 9.0x10-9 M (Leng, Metz et al. 2003). These data indicate that Lm1740MIF binds to 
the human MIF receptor with decent affinity, albeit with a 3-fold lower Kd than 
recombinant human MIF. 
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Fig. 12.  Lm1740MIF binds to the MIF receptor, CD74.  Real-time surface plasmon resonance 
analysis (BIAcore) of the interaction between recombinant Lm1740MIF and sCD74.  A Kd of 
2.9×10-8 M for the binding between Lm1740MIF and sCD74 was measured. 
 
4.4 Lm1740MIF inhibits monocyte/macrophage apoptosis  
Leishmania-infected macrophages survive longer and are more viable than uninfected 
macrophages (Moore and Matlashewski 1994).  An important function of MIF is to 
activate macrophages and lead to ERK1/2 phosphorylation.  MIF activates ERK and 
acts downstream to maintain monocyte/macrophage function by inhibiting activation 
induced p53-dependent apoptosis (Mitchell, Liao et al. 2002).  It was hypothesized 
that Lm1740MIF may contribute to parasitism by prolonging the survival of infected 
macrophages through inhibition of apoptosis. 
 
4.4.1 Signal transduction in wild-type mice 
MIF signal transduction through CD74 results in the activation of the ERK1/2 
mitogen-activated protein kinase (MAPK) pathway (Mitchell, Metz et al. 1999).  
Downstream of ERK1/2 activation, the antiapoptotic action of MIF is associated with 
a reduction in the intracytoplasmic content of Ser15-phosphorylated p53, which 
increases in response to NO treatment (Mitchell, Liao et al. 2002).  It was examined 
whether Lm1740MIF inhibits apoptosis in bone marrow-derived macrophages, both 
to confirm its biological activity and to assess its ability to influence host-cell 
responses when present in the extracellular milieu.  The effect of Lm1740MIF was 
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less than that observed with murine MIF (Fig. 13).  Protection from apoptosis 
occurred after incubation of bone-marrow derived macrophages with Lm1740MIF 
and induction of apoptosis with SNP (an NO donor).  This result was associated with 
a diminuition in the cellular content of Ser15-phosphorylated p53 (Fig. 14).  
Furthermore, it was shown that Lm1740MIF also induced ERK1/2 phosphorylation in 
primary murine macrophages (Fig. 14).   
 
 
 
 
Fig. 13.  Lm1740MIF protects macrophages from SNP-induced apoptosis. Wild-type (WT) bone 
marrow-derived macrophages were treated with either Lm1740MIF or murine MIF prior to the 
addition of the apoptosis inducer, SNP.  Negative controls did not include SNP addition.  DNA 
fragmentation was assessed by ELISA after 36 hrs.  The p values were calculated using the 
Student’s t test.  **p<0.01, *p<0.05 for MIF versus SNP controls.  **p<0.01, *p<0.05 for 
Lm1740MIF versus MIF.  **p<0.01 for control versus SNP addition.  The values for p>0.05 are 
not displayed.  Results are representative of at least four independent experiments.  
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Fig.14. Lm1740MIF induces phosporylation of ERK1/2 and inhibits p53 phosphorylation. Wild-
type (WT) bone marrow-derived macrophages were treated with Lm1740MIF or murine MIF at 
the concentrations shown prior to the addition of the apoptosis inducer, SNP, as indicated in 
Material and Methods.  Negative controls were conducted by not stimulating cell death with SNP.  
The phosphorylation of ERK1/2 and p53 was assessed by Western blotting using specific 
phospho-ERK1/2, total ERK1/2, phospho-p53, and total p53 antibodies.  The western blots are 
representative of at least four independently performed experiments.  
 
4.4.2 ERK1/2 activation by endotoxin 
Because ERK1/2 activation in macrophages may be induced by endotoxin (LPS), 
ERK1/2 activation by Lm1740MIF was additionally tested in macrophages from 
C3H/HeJ mice that have a loss-of-function mutation in the LPS receptor, Toll-like 
receptor 4 (TLR4) (Poltorak, Ricciardi-Castagnoli et al. 2000).  A dose-dependent 
increase in ERK1/2 phosphorylation in response to Lm1740MIF was also observed in 
these cells.  
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Fig. 15.  ERK1/2 phosphorylation serves as a control against LPS contamination.  C3H/HeJ bone 
marrow-derived macrophages were treated with either Lm1740MIF or murine MIF at the 
concentrations shown prior to the addition of the apoptosis inducer, SNP, as indicated in the 
Material and Methods.  The phosphorylation of ERK1/2 was assessed by Western blotting using 
specific phospho-ERK1/2 and total ERK1/2 antibodies.  Results are representative of at least four 
independent experiments.  
 
4.4.3 Signal transduction in CD74-knockout mice 
The functional requirement for the MIF receptor in Lm1740MIF action was further 
examined by studying both the signaling and apoptotic responses of macrophages 
obtained from mice deficient in CD74.   
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Fig. 16. Lm1740MIF did not protect CD74-KO macrophages from SNP-induced apoptosis. CD74-
knockout bone marrow-derived macrophages were treated with either Lm1740MIF or murine MIF 
prior to the addition of the apoptosis inducer, SNP.  DNA fragmentation was assessed by ELISA 
after 36 hrs.  The p values were calculated using the Student’s t test.  ***p<0.001 for control 
versus SNP addition.  The p values for comparisons with p>0.05 are not displayed.  Results are 
representative of at least four independent experiments.  
 
Differences in the SNP effect between WT and CD74-KO macrophages can be 
attributed to the indirect testing principle of the ELISA method. This method does not 
measure the apoptosis rate of the samples directly but the conversion of ABTS in the 
presence of hydrogen peroxide into a green end-product. For starting the ABTS 
reaction there are more than seven necessary intermediate steps which all allow a 
certain inaccuracy in the end result leading to the differences seen between the 
controls of WT and CD74-KO macrophages. 
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Fig. 17. Lm1740MIF did not induce phosporylation of ERK1/2 or inhibit p53 phosphorylation in 
CD74-KO macrophages. Bone marrow-derived macrophages from MIF receptor-deficient (CD74-
KO) mice were prepared and studied for protection from apoptosis, ERK1/2 phosphorylation, and 
phospho-p53 content as described in Material and Methods.  Results are representative of at least 
four independent experiments.  
 
 
The treatment of bone marrow-derived macrophages from CD74 receptor-deficient 
(CD74-KO) mice with either mammalian MIF or Lm1740MIF did not have the same 
effects as treatment of cells from wild-type mice.  Murine MIF was not active in these 
cells, which is in agreement with prior reports (Leng, Metz et al. 2003; Shi, Leng et 
al. 2006) and there was no effect of Lm1740MIF with respect to protection from 
apoptosis, intracellular phospho-p53 content or ERK1/2 phosphorylation (Figs. 16 
and 17).  These data show that CD74 is necessary for Lm1740MIF signaling as it is 
for MIF.  Quantification of the blots was not carried out since inhibition of apoptosis 
was shown by ELISA.   
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5 Discussion 
The increasing incidence of vector-borne diseases is thought to be a result of global 
warming associated with extreme weather events as well as annual changes in weather 
conditions.  In addition, increases in infectious disease outbreaks (Sutherst 2004; 
Khasnis and Nettleman 2005) have resulted from the growth of international travel 
that elevates the risk of importing vector-borne diseases from tropical areas (Weitzel, 
Muhlberger et al. 2005).  Therefore, obtaining a better understanding of vector-borne 
diseases will aid in the control of such outbreaks.   
This thesis focused on the description of two orthologs (with an emphasis on 
Lm1740MIF) of the pro-inflammatory cytokine, macrophage migration inhibitory 
factor (MIF); these orthologs are produced by the obligate intracellular parasite, 
Leishmania major.  Several primitive eukaryotes were also found to encode MIF-like 
genes that show remarkable similarity with the mammalian gene, such as the human 
parasitic nematodes Brugia malayi (Pastrana, Raghavan et al. 1998) and Ancylostoma 
ceylonicum (Cho, Jones et al. 2007).  The tick vector responsible for the transmission 
of anaplasmosis, Amblyomma americanum, produces an MIF ortholog that is 
expressed in the salivary gland (Jaworski, Jasinskas et al. 2001).  MIF-like proteins 
also have been reported recently in the pathogenic species Eimeria (Miska, Fetterer et 
al. 2007), Trichinella (Wu, Boonmars et al. 2003), and Plasmodium (Augustijn, 
Kleemann et al. 2007; Cordery, Kishore et al. 2007), and the question has been raised 
as to whether these proteins play a role in parasite-host interactions. 
MIF was demonstrated to reduce the number of Leishmania parasites in infected 
macrophages (Juttner, Bernhagen et al. 1998).  Noteworthy is the finding that 
macrophages are activated by the simultaneous addition of IFN-γ and MIF even 
though these factors act independently of one another.  Leishmanicidal effects elicited 
by MIF follow TNF-α-induced macrophage activation and the production of 
endogenous NO by these activated macrophages.  MIF is assumed to inhibit 
monocyte/macrophage migration after entering the site of infection to protect the host 
from infected phagocytes.  MIF levels increase in the host after L. major infection, 
resulting in an immune response. 
A molecular biological approach to further elucidate the functional characteristics of 
the L. major MIF orthologs was chosen to study LmMIF in the host immune response 
as well as MIF’s function in the parasite’s immune-evasion machinery.  
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5.1 Computational analysis 
Phylogenetics is the study of evolutionary relatedness among various groups of 
organisms (e.g., species, populations).  Phylogenetic analysis using the Neighbor-
Joining method (Saitou and Nei 1987) surprisingly revealed that L. major and L. 
infantum MIF genes were more closely related to one another than to MIF orthologs 
within the same species.  This finding substantiates the hypothesis that Lm1740MIF 
and Lm1750MIF are paralogous genes, originating from gene duplication of the same 
ancestral gene.  From the primary structural similarities between Leishmania and 
mammalian MIF sequences, it follows that LmMIF and MIF are orthologs, related to 
a common ancestor and having similar, if not the same, cellular functions.  These 
functions were further determined during the course of this thesis.  Lm1740MIF and 
Lm1750MIF were found to be 58% identical to one another.  Compared with human 
MIF (hMIF), Lm1740MIF and Lm1750MIF were found to be 13% and 10% identical 
and 22% and 13% homologous, respectively.  The majority of experiments in this 
thesis were carried out using Lm1740MIF, since Lm1740MIF was more structurally 
similar to hMIF than was Lm1750MIF. 
The amino acid-sequence alignment of twelve selected members of the MIF protein 
family shows the existence of nine invariant residues of MIF (Pro1, Leu21, Gly34, 
Lys35, Pro36, Phe52, Gly54, Gly68, and Phe116).  Mammalian MIF is distinguished 
by the presence of three conserved cysteines (Cys57, Cys60, and Cys81 or 56,59,80, 
depending on whether you count the Met-1), the first two of which define a CXXC 
motif that mediates thiol-protein oxidoreductase activity (Nguyen, Beck et al. 2003).  
These conserved cysteines, as well as the CXXC motif itself, are absent in 
Leishmania sequences, though they satisfy requirements of the “extended” TPOR 
sequence with a Phe at position -7 (Kleemann, Kapurniotu et al. 1998).  The MIF N-
terminal proline residue (Pro1) by contrast appears to be strictly conserved, with the 
exception of the grossly truncated L. braziliensis sequence.  Pro1 functions as a 
catalytic base for substrate tautomerization (whether a physiological substrate exists is 
unknown (Swope and Lolis 1999)); this residue has been shown by X-ray 
crystallography to reside within a hydrophobic, substrate-binding pocket of 
mammalian proteins (Bendrat, Al-Abed et al. 1997; Stamps, Fitzgerald et al. 1998; 
Lubetsky, Swope et al. 1999).  
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The finding of trypanosoma-specific putative TATA boxes and polyadenylation 
signals in the flanking regions of both Lm1740MIF and Lm1750MIF led to the 
assumption that these two genes are expressed in vivo and have functional activity.  
Furthermore, this discovery further supports the hypothesis that Lm1740MIF and 
Lm1750MIF originated via gene duplication.  This finding elicited the analysis of 
MIF expression in L. major parasites. 
 
5.2 Investigation of L. major MIF expression in vivo 
Both reverse transcription-PCR and qPCR are techniques highly applicable for the 
gene expression analysis of developmentally regulated genes.  These analyses are 
crucial to the understanding of biological gene function (Ding and Cantor 2004).  
Normalization of gene levels with stably expressed reference genes is critical for the 
generation of reliable results with biological significance.  This is particularly true for 
pathogens, like Leishmania parasites, that alternate between three different 
developmental stages during their life cycles.  Developmental stage-specific gene 
expression experiments were performed on total RNA (reverse-transcribed into 
cDNA) isolates from all L. major life stages (procyclic, metacyclic and amastigote 
parasites) using real-time qPCR.  Expression of the target genes was related to the 
stable expression of internal controls, also referred to as “housekeeping genes,”  
simultaneously determined in the same sample (Huggett, Dheda et al. 2005).  The 
sequences encoding rRNA45 and ADP/ATP carrier were stably expressed in all 
developmental stages of the parasite (Leifso, Cohen-Freue et al. 2007; Ouakad, Bahi-
Jaber et al. 2007) and were thus used as reference genes in the gene expression studies 
of Lm1740MIF and Lm1750MIF in L. major.   
This study revealed that both Lm1740MIF and Lm1750MIF were expressed in vivo 
throughout all Leishmania life stages.  However, Lm1750MIF had higher expression 
levels than Lm1740MIF during all life-stages of the parasite; the highest expression of 
both LmMIF forms was in the procyclic life-stage of the parasite.  This distribution 
pattern might point towards a yet unexplored role of LmMIF, especially of 
Lm1750MIF, within the sand-fly vector.  A closer examination of whether these 
proteins function as virulence factors or in metacyclogenesis that leads to infective 
metacyclic parasites is imperative to undertake in future experiments. 
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5.3 Binding of Lm1740MIF to the human macrophage MIF receptor, 
CD74 
The possibility that Lm1740MIF influences host immunity prompted us to examine 
whether Lm1740MIF binds to the human MIF receptor, CD74 in macrophages.  In 
addition to its interaction with the CXCR chemokine receptors, MIF activates cells by 
engaging its cell surface-binding receptor, CD74.  A high-affinity binding interaction 
between MIF and the CD74 ectodomain (CD7473-232 or sCD74) had previously been 
demonstrated by BIAcore analysis (Leng, Metz et al. 2003).     
BIAcore analysis measures real-time binding interactions by changes in the refractive 
index of a biospecific surface and generates unique data on protein-protein 
interactions.  The extent to which a molecule interacts with a single partner 
immobilized on a sensor surface reveals the specificity of the interaction. 
During this thesis, the equilibrium dissociation constant was measured for the binding 
of Lm1740MIF to sCD74 by surface plasmon resonance (BIAcore analysis).  BIAcore 
measurements revealed a Kd of 2.9×10-8 M for the binding between Lm1740MIF and 
sCD74. These data indicate that Lm1740MIF binds to the human MIF receptor with 
decent affinity.  This value contrasts with a previously determined Kd for the binding 
of human MIF with sCD74 of 9.0×10-9 M to 2.3×10-10 M (Leng, Metz et al. 2003).  
These data indicate that Lm1740MIF binds to the human MIF receptor CD74 with 
high affinity, albeit with a 3-fold lower Kd than that of human MIF.  Nevertheless, 
there is sufficient structural homology between Lm1740MIF and human MIF to allow 
strong binding to CD74. 
The finding that Lm1740MIF interacts with CD74 is preliminary; many more 
experiments, especially interaction studies in complementing assay systems such as 
cellular binding assays, receptor internalization assays, or CoIPs must be performed 
before further conclusions about this interaction can be made.  
Future experiments shall also include studies of Lm1740MIF secretion by L. major, a 
pathophysiological prerequisite to enable CD74 binding to occur.  The determination 
of the surface contacts between Lm1740MIF and CD74 and the identification of 
inhibitors of this interaction are additional tasks that need to be addressed. 
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5.4 Impact of Lm1740MIF on CD74-mediated signal transduction 
Signal transduction refers to the transmission of signals from the outside of the cell to 
the inside of the cell that involves the coupling of a ligand to its receptor.  This 
interaction induces many intracellular events, including phosphorylation of a variety 
of cellular kinases and transcription factors.  Protein phosphorylation can alter protein 
activity and/or protein conformation with an eventual outcome of altered cellular 
activity.  
An important biologic action of the cytokine MIF is to sustain monocyte/macrophage 
function by inhibiting activation-induced, p53-dependent apoptosis (Mitchell, Liao et 
al. 2002).  Transient transfection of an MIF-expressing plasmid into RAW264.7 
macrophages inhibits apoptosis by an autocrine/paracrine pathway involving the 
CD74 membrane receptor (Mitchell, Liao et al. 2002; Shi, Leng et al. 2006).  The 
comparative ability of plasmids encoding murine MIF, Lm1740MIF, and 
Lm1750MIF to protect cells from NO-mediated apoptosis was tested in a model 
system.  Both Leishmania MIF orthologs inhibited apoptosis in a dose-dependent 
fashion, but at levels that were approximately 30% lower than that of transfected 
murine MIF (“MSc thesis”; Diplomarbeit). 
It was postulated that Lm1740MIF contributes to parasitism by prolonging the 
survival of the infected macrophage, leading to its longevity.  
To confirm the results of previous transfection experiments (“MSc thesis”; 
Diplomarbeit) and to evaluate the functional significance of the binding interaction 
between Lm1740MIF and CD74, the ability of recombinant Lm1740MIF to inhibit 
apoptosis of primary macrophages was examined.  Additionally, known targets of 
MIF were analyzed to confirm the biological activity of Lm1740MIF and to assess the 
ability of Lm1740MIF to influence host-cell immune responses when present in the 
extracellular milieu. 
The effect of Lm1740MIF was decreased compared to that of murine MIF, which is 
consistent with both the transfection data (“MSc thesis”; Diplomarbeit) as well as its 
reduced receptor binding activity.  MIF signal transduction through CD74 is known to 
result in the activation of the ERK1/2 MAPK pathway (Mitchell, Metz et al. 1999), 
and Lm1740MIF was also shown to be capable of inducing ERK1/2 phosphorylation 
in primary murine macrophages.   Because ERK1/2 activation in macrophages may be 
induced by endotoxin (LPS), which is present in trace quantities in recombinant 
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Lm1740MIF (< 20 pg LPS/µg protein), Lm1740MIF was additionally tested in 
macrophages from C3H/HeJ mice, which have a loss-of-function mutation in TLR4 
(Poltorak, Ricciardi-Castagnoli et al. 2000).  A dose-dependent increase in ERK1/2 
phosphorylation in response to endogenous Lm1740MIF was observed in these cells, 
arguing against a role for contaminating endotoxin in Lm1740MIF-induced ERK1/2 
phosphorylation.   
After treatment with the NO donor, SNP, macrophage life spans are prolonged 
through MIF, which is associated with a reduction in the intracytoplasmic content of 
phosphorylated Ser15 of p53 (Mitchell, Liao et al. 2002).  Lm1740MIF was shown to 
induce protection from apoptosis after exposure of bone marrow-derived 
macrophages to NO; this protection was associated with a diminution in the cellular 
content of Ser15-phosphorylated p53 as well.  
While differences in the relative ability of Lm1740MIF versus murine MIF to affect 
changes in phosphorylation may be evident, quantitative comparisons are difficult to 
make given the narrow linearity of signals that is apparent by Western blotting. These 
results nevertheless indicate that Lm1740MIF is biologically active when added to 
mammalian cells and, like mammalian MIF, stimulates ERK1/2 phosphorylation and 
reduces the cellular content of phospho-p53 that leads to macrophage longevity. 
Finally, the functional requirement for the human MIF receptor CD74 in Lm1740MIF 
action was examined by studying the signaling and apoptotic responses of 
macrophages obtained from mice deficient in the CD74 receptor.  Murine MIF was 
inactive in these cells in agreement with previous reports (Leng, Metz et al. 2003; Shi, 
Leng et al. 2006).  Similar to mouse MIF, apoptosis protection by Lm1740MIF was 
dependent on the presence of CD74 and, therefore, Lm1740MIF had no effect on 
CD74-KO primary macrophages with respect to protection from apoptosis, ERK1/2 
phosphorylation, or intracellular phospho-p53 content in CD74-/- mice.  
Taken together, these data support the conclusion that the Leishmania ortholog, 
Lm1740MIF, activates the human MIF receptor CD74 and influences host cell 
responses, specifically monocyte/macrophage survival, by engaging CD74.  The 
mechanism by which Lm1740MIF interacts with CD74 is not yet known.  It is 
possible that Lm1740MIF is secreted by the parasite after infection and binds to 
CD74 upon interaction with macrophages.  Alternatively, Lm1740MIF may be 
secreted after internalization of the parasite into a macrophage and be released from 
the cell and bind to CD74 as was reported for MIF (Flieger, Engling et al. 2003).  One 
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might speculate that the interaction with CD74 may also occur intracellularly by 
gaining access to the endosomal compartment (Kleemann, Hausser et al. 2000). 
 
5.5 Concluding remarks 
Leishmania is an intracellular infection of monocytes/macrophages; therefore, one 
function of Leishmania-encoded MIF may be to sustain monocyte/macrophage 
longevity that contributes to the persistence of the parasite within host cells for 
completion of the parasitic life cycle. To measure LmMIF concentration in 
macrophages and to find out which other proteins interact with LmMIF, how and 
where LmMIF moves within the cell and how LmMIF responds to changes in cell 
conditions, LmMIF tagging approaches have started to be undertaken.  The precise 
cellular pathway by which Lm1740MIF activates CD74 remains to be investigated 
though it appears from the herein reported results that Lm1740MIF binds to the 
extracellular C-terminal domain of CD74. An additional question posed by these 
findings is whether there exist further, functional roles for Leishmania MIF with 
respect to the host-parasite interaction.  It is noteworthy that MIF binding to CD74 
was shown recently to affect recruitment and activation of additional signaling 
proteins, including CD44 (Shi, Leng et al. 2006), as well as the chemokine receptors, 
CXCR2 and CXCR4 (Bernhagen, Krohn et al. 2007).  Whether Lm1740MIF 
modulates additional pathways that are important for intracellular parasitism or 
immune evasion but are not activated by mammalian MIF remains to be determined/ 
For this purpose microarray analysis have already been started to be carried out, but 
their in-depth analysis, confirmation by Northern blot and quantitative PCR, and 
interpretation fall without of the time-frame and scope of this thesis.  It is also notable 
that while host-derived MIF may augment the killing of L. major, its specific activity 
is low compared with cytokines, such as IFN-γ (Juttner, Bernhagen et al. 1998).  
While our data are consistent with a role for Leishmania MIF in modulating the host 
immune response, they exclude neither the intrinsic function for Lm1740MIF in the 
growth or replication of the parasite nor the function of LmMIF in promastigotes 
within the parasitic vector.  
Two mif-like genes were described to be transcriptionally upregulated in the dauer 
stage of the free-living nematode, C. elegans.  It has been hypothesized that these 
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genes may have a homeostatic role during adverse conditions that cause 
developmental arrest (Marson, Tarr et al. 2001). 
A physiologic role for Leishmania MIF in the parasitic life cycle and a closer 
examination of whether these proteins function as virulence factors may be attained 
by creating different strains of Leishmania that lack MIF orthologs.  Such studies, as 
well as the identification of the surface contacts between MIF and the CD74 surface 
receptor, may also provide support for selective, pharmacologic targeting of 
Leishmania MIF for therapeutic benefit.  Another interesting aspect of Leishmaniasis 
with respect to MIF is the study of the MIF promotor region to determine patient 
genotypes and assess whether MIF expression levels can be linked to disease severity 
and outcome.  Unfortunately, these interesting questions have been outside the scope 
of this thesis. 
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6 Summary 
Parasitic organisms have evolved specialized strategies to evade host immune defense 
mechanisms.  This thesis describes the characterization of two Leishmania major-
encoded orthologs of the pro-inflammatory pleiotropic cytokine, macrophage 
migration inhibitory factor (MIF).  These two MIF-like sequences show 22% 
sequence identity when aligned with human MIF, and are most likely the result of 
gene duplication.  
The Lm1740MIF and Lm1750MIF genes (58% identity) are expressed in all 
developmental stages of L. major.  Interestingly, LmMIF expression levels were 
shown to be significantly up-regulated in the procyclic life-stage of the parasite, 
which exists solely in the host sand fly.  Furthermore, Lm1750MIF levels were 3–4 
fold higher than Lm1740MIF levels.  The finding that LmMIF is expressed in 
procyclic parasites might reveal a new function for MIF within its vector, the sandfly. 
Furthermore, the work described here postulated that Lm1740MIF might interact with 
the macrophage surface receptor, CD74.  To evaluate this hypothesis, binding 
analyses using surface plasmon resonance (Biacore) were carried out.  The Kd of MIF 
was previously approximated to be between 9 × 10-9 to 2.3 × 10-10.  Lm1740MIF 
showed a significant binding interaction with CD74 (Kd = 2.9 × 10-8 M).  Thus, there 
is sufficient structural homology between Lm1740MIF and human MIF to permit 
high-affinity binding to CD74.   
To investigate whether Lm1740MIF induces ERK1/2 activation in a CD74-dependent 
manner and to determine if it inhibits activation-induced macrophage apoptosis 
similar to its mammalian counterpart, the ability of Lm1740MIF to stimulate ERK1/2 
phosphorylation as well as to inhibit Ser15 phosphorylation of the tumor suppressor 
p53 was tested.  Macrophages treated with Lm1740MIF were assessed for apoptosis 
by the ELISA method; additionally, Western blot analyses for ERK1/2 and p53 
activation were performed.  The interaction between Lm1740MIF and CD74 led to a 
similar signal transduction response in macrophages obtained from both wild-type and 
C3H/HeJ mice, indicating that signaling was not due to the presence of contaminating 
endotoxin. 
Lm1740MIF was functionally active in both ERK1/2 signaling and protection from 
apoptosis, although the level of activity was generally lower than for mammalian 
MIF, an observation that appeared consistent with the lower Kd of Lm1740MIF for 
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the CD74 receptor.  For mouse MIF, protection from apoptosis was dependent on 
CD74, and the response was associated with a decrease in the cytoplasmic content of 
Ser15-phosphorylated p53.  The ability of Lm1740MIF to inhibit apoptosis may 
facilitate the persistence of Leishmania within macrophages and contribute to its 
evasion from immune destruction.  The precise cellular pathway by which 
Lm1740MIF activates CD74 and whether Lm1740MIF modulates additional 
pathways that are important for either intracellular parasitism or for immune evasion 
remains to be determined. 
In conclusion, the presented results indicate that a Leishmania ortholog of the 
cytokine MIF has the ability to activate the human MIF receptor and influence the 
functional responses of monocytes/macrophages.  Because Leishmania is an 
intracellular infection of monocytes/macrophages, Leishmania-encoded MIF is 
hypothesized to sustain monocyte/macrophage survival and contribute to the 
persistence of the parasite for completion of its infectious life cycle.  While these data 
are consistent with a role for Leishmania MIF in modulating host-immune responses, 
they do not exclude the possibility that Lm1740MIF may function in the growth 
and/or replication of the parasite.   
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